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ABSTRACT 
Background 
The meningococcal capsule is an important virulence determinant. Unencapsulated 
meningococci lacking capsule biosynthesis genes and containing the capsule null locus (cnl) 
are predominantly non-pathogenic. Rare cases of invasive meningococcal disease caused by 
cnl isolates belonging to sequence types (ST) and clonal complexes (cc) ST-845 (cc845), ST-
198 (cc198), ST-192 (cc192) and ST-53 (cc53) have been documented. The clinical 
significance of these isolates however remains unclear. We identified four invasive cnl 
meningococci through laboratory-based surveillance in South Africa from 2003 through 2013, 
which we aimed to characterize using whole genome data.  
Results  
One isolate [NG: P1.7-2,30: F1-2: ST-53 (cc53)] contained cnl allele 12, and caused 
empyema in an adult male with bronchiectasis from tuberculosis, diabetes mellitus and a 
smoking history. Three isolates were NG: P1.18-11,42-2: FΔ: ST-192 (cc192) and contained 
cnl allele 2. One patient was an adolescent male with meningitis. The remaining two isolates 
were from recurrent disease episodes (eight months apart) in a male child with deficiency of 
the sixth complement component, and with the exception of two single nucleotide 
polymorphisms, contained identical core genomes. The ST-53 (cc53) isolate possessed alleles 
for NHBA peptide 191 and fHbp variant 2; whilst the ST-192 (cc192) isolates contained 
NHBA peptide 704 and fHbp variant 3. All four isolates lacked nadA. Comparison of the 
South African genomes to 65 additional cnl genomes on the PubMLST Neisseria database 
(http://pubmlst.org/neisseria/), determined that most putative virulence genes could be found 
in both invasive and carriage phenotypes. 
Conclusions 
Although rare, invasive disease by cnl meningococci may be associated with host 
immunodeficiency and such patients may benefit from protein-based meningococcal vaccines. 
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CHAPTER ONE: LITERATURE REVIEW 
1.1. Background 
Neisseria meningitidis (meningococcus) is a commensal bacterium of the human upper respiratory 
tract but is also an important cause of septicemia and meningitis, particularly in children less than 
five-years-old and young adults (6-13). Approximately 1.2 million cases of invasive meningococcal 
disease (IMD) are reported globally, per annum; with ~10% of IMD cases being fatal and up to 20% 
of survivors experiencing long-term sequelae such as deafness, limb amputation and mental 
impairment (14;15). Further, the meningococcus is transmitted via aerosolized respiratory secretions 
and may cause large scale outbreaks (16;17). The rapid disease manifestation, devastating long-term 
complications and significant impact on public health makes precise identification and 
characterization of N. meningitidis an important aspect for the monitoring, control and prevention of 
IMD.  
 
The first well described outbreak of meningococcal disease was by Vieusseux and occurred in 1805 
in Geneva, Switzerland (18). It was only in 1887, that Weichselbaum successfully isolated the 
etiological agent from the cerebrospinal fluid (CSF) of six fatal cases of IMD, and named it 
‘Diplococcus intracellularis meningitidis’. The asymptomatic carriage state of the meningococcus 
precedes IMD and was later established in 1896, whereby Kiefer isolated the bacterium from throat 
swabs taken from healthy carriers.  
 
N. meningitidis is a Gram-negative diplococcus that is oxidase and catalase positive, and may be 
differentiated from other Neisseria spp. by fermentation of glucose and maltose (Figure 1 A) (19). 
Meningococci are fastidious and grow optimally on blood-enriched media, incubated in a moist 
environment between 35-37°C and containing 5% CO2. The bacterium is non-haemolytic and 
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appears as smooth, translucent/ grey colonies which are convex in shape (Figure 1 B). In addition, 
meningococci may be encapsulated or unencapsulated.  
 
 
 
 
 
Figure 1. Microbiological characteristics of Neisseria meningitidis. A) Gram’s stain of 
N. meningitidis (American Type Culture Collection (ATCC) 13077, serogroup A), showing Gram-
negative diplococci (X1000). B) A 24 hour (hr) culture of N. meningitidis (ATCC 13077, serogroup 
A) on 5% horse blood agar showing convex, smooth, translucent/ grey colonies which are non-
haemolytic.  
A 
B 
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1.2. Phenotypic characterization of N. meningitidis using the polysaccharide capsule 
The polysaccharide capsule is regarded as an important virulence determinant, and promotes 
survival of the meningococcus in the bloodstream by preventing complement-mediated lysis 
and opsonophagcytosis (20-23). Further, most cases of IMD are caused by encapsulated 
strains (6-13). Twelve antigenically different polysaccharide capsules have been described, 
and classify the bacterium into serogroups (A, B, C, E, H, I, K, L, W, X, Y and Z) (24). In 
addition, the meningococcal capsule is an important component of polysaccharide-based 
vaccines which target serogroups A, C, W and Y.  
 
The first meningococcal serological typing scheme was described in 1915 by Gordon and 
Murray (25), which classified N. meningitidis into types I-IV. The typing scheme was revised 
in 1950 by the Subcommittee on the Family Neisseriaceae of the International Committee on 
Bacteriological Nomenclature (International Association of Microbiologists), and classified 
N. meningitidis into serogroups A, B, C and D (26). Serogroups X, Y and Z were 
subsequently described in 1961; E (previously 29E or Z’) and W (previously 135 or W135) in 
1968; H, I and K in 1981 and L in 1983 (27-31).  
 
Enzymes for capsular synthesis and transport are encoded by a single cluster of genes, termed 
the capsular polysaccharide synthesis (cps) locus (Figure 2) (24). The cps locus is divided into 
six regions which are arranged in order of D-A-C-E-D’-B. Enzymes for polysaccharide 
synthesis are encoded by genes in region A, which vary according to serogroup and are 
therefore used to design genogrouping assays (24;32). Genes in regions B (ctrE-ctrF) and C 
(ctrA-ctrD) encode enzymes for transport of capsular material (33). Region D comprises non-
functional rhamnose biosynthetic pathway genes (rfbA- rfbC), and galE which is involved in 
lipopolysaccharide (LPS) biosynthesis; whilst region D’ is a truncated, non-functional version 
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of region D (34). Region E is not involved in polysaccharide synthesis nor transport, but is 
hypothesized to be involved in the regulation of these processes (35). Meningococci 
belonging to serogroup D were determined to be unencapsulated based on the fact that they 
contained serogroup C genes and internal stop codons in ctrA and ctrE, and did not 
agglutinate with antisera (24). 
 
Non-groupable refers to a meningococcal isolate which cannot be classified into one of the 12 
defined serogroups, using phenotypic and genotypic methods. Slide agglutination 
serogrouping assays are based on antigen-antibody binding, and a positive result is indicated 
by agglutination with one serogroup-specific antiserum and a negative saline control (36). 
Serological assays are however subjective as the intensity of the reaction is reliant on the 
density of the cell suspension and quality of antiserum used. On occasion, some meningococci 
may agglutinate with more than one serogroup-specific antiserum and are termed as 
‘polyagglutinating’, e.g. isolates expressing more than one capsule phenotype (37-39). In 
addition, some meningococci do not agglutinate and are regarded as ‘non-reactive’, or 
agglutinate in the saline control and are classified as ‘autoagglutinating’; both of which may 
occur as a result of capsule loss due to horizontal genetic exchange, slipped-strand mispairing, 
point mutations or gene deletion in the cps locus (40-42). According to Castillo et al. (36), 
polyagglutinating, non-reactive and autoagglutinating meningococci are reported as ‘non-
groupable’. Although genogrouping assays such as real-time polymerase chain reaction (RT-
PCR) directly infer serogroup information from nucleotide sequences, these assays do not 
indicate capsule expression (32). Genome data may be used to provide additional resolution 
for determining mechanisms for non-groupability (39;43).  
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The presence of a polysaccharide capsule may be confirmed using transmission electron 
microscopy (TEM). However, polysaccharide capsules are hydrated structures and are 
difficult to preserve during sample preparation. Previous protocols to address this problem 
included the use of cationic dyes such as ruthenium red or alcian blue, together with fixatives 
including formaldehyde and glutaraldehyde with the addition of L-lysine acetate (primary 
fixation), and osmium tetroxide (post-fixation) (1;44;45). These methods were however not 
universal as capsular staining may depend on the cell wall composition (Gram-positive or 
Gram-negative) and the cationic dye used (1). Results from both phenotypic and genotypic 
assays should therefore be considered to confirm the presence and expression of cps genes.
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Figure 2. Arrangement and nomenclature of genes in the Neisseria meningitidis capsular polysaccharide synthesis (cps) locus for the six most common 
invasive serogroups A (isolate Z2491, GenBank accession no. AL157959), B (H44/76, CP002420), C (FAM18, AM421808), W (WUE171, HF562992), X 
(α388, HF562988) and Y (α162, HF562989), adapted from Harrison et al. (24).The cps is divided into six regions arranged in order of D-A-C-E-D’-B, and 
genes in region A vary according to serogroup. Meningococci containing the capsule null locus (cnl) (5957, PubMLST accession no. 29312) lack the genes 
required for polysaccharide synthesis (region A) and transport (region B and C). 
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1.3. Molecular characterization 
1.3.1. Outer membrane proteins 
Meningococci of the same capsular type (serogroup) are genetically and antigenically 
diverse, and capsular typing alone does not provide sufficient data for IMD surveillance. 
Typing of meningococcal outer membrane proteins (OMP) provides additional strain 
information such as serotype and serosubtype. Meningococcal OMP’s are categorized into 
five classes based on molecular weight (46). Serosubtyping is based on porin A (PorA), 
which is a class 1 (46 kDa) OMP and denoted as P1. (47). The PorA protein structure 
contains eight surface-exposed loops with the highest amino acid diversity observed in loops 
I and IV, which bind to monoclonal antibodies in serological assays (48). Loops I and IV are 
designated as major variable regions (VR) and are referred to as VR1 and VR2, respectively. 
Serotyping is based on the porin B (PorB) antigen which possesses class 2 (41 kDa) or 3 (38 
kDa) homology (49).  
  
Due to the high variability of OMP’s, monoclonal antibody panels do not encompass all 
known antigen variants (50). In addition, serological assays rely on culture positive 
specimens and expression of the relevant target, and results are poorly reproducible (51;52). 
To address these problems, molecular typing schemes for meningococcal characterization 
were developed and are hosted on the PubMLST Neisseria database 
(http://pubmlst.org/neisseria/) (53). The PubMLST Neisseria database is publically available 
and regularly updated, and provides a standardized platform for comparison of data between 
different laboratories. The PubMLST Neisseria database hosts antigen typing schemes for 
PorA VR1 and VR2 (porA) (54), PorB (porB) (55), the ferric enterochelin receptor (fetA) (56) 
and antigens which are included in OMP vaccine formulations including factor H-binding 
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protein (fHbp) (57), neisserial adhesin A (nadA) (58;59) and neisserial heparin-binding 
antigen (nhba) (60).  
 
The FetA antigen is expressed under conditions of iron limitation and may be classified into 
one of five families, based on loop VII (61;62). The meningococcal fHbp antigen recruits 
factor H to the bacterial surface to avoid complement-mediated lysis (63). The fHbp antigen 
may be classified into three variants (variants 1-3) (64) or two subfamilies (A and B) (65). 
Subfamily A corresponds to variants 2 and 3, and subfamily B corresponds to variant 1. The 
NadA antigen is involved in adhesion and invasion of human epithelial cells, and is 
predominantly associated with invasive meningococci as opposed to carriage strains 
(58;59;66). The NHBA antigen binds heparin and increases resistance to killing by human 
sera, as well as contributes to adhesion to human epithelial cells (60;67).  
 
1.3.2. Multilocus sequence typing 
Loci which encode OMP’s are highly variable and do not provide information on 
meningococcal population structure. The multilocus enzyme electrophoresis (MLEE) 
approach was previously used to detect microevolution in a bacterial populations, based on 
the electrophoretic movement of metabolic enzymes which are encoded by conserved 
housekeeping loci (68). However, MLEE data are poorly reproducible and difficult to 
compare amongst laboratories. Alternatively, meningococcal population structure may be 
determined by directly indexing variation in the nucleotide sequences of housekeeping genes 
(fragment size ~500 bp), using multilocus sequence typing (MLST) (69). Multilocus 
sequence typing data are therefore unambiguous, reproducible, standardized and may be 
readily compared between laboratories using the PubMLST Neisseria database. 
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The nucleotide sequences of seven housekeeping genes i.e., abcZ (putative ABC transporter), 
adk (adenylate kinase), aroE (shikimate dehydrogenase), fumC (fumaratehydratase), gdh 
(glucose-6-phosphate dehydrogenase), pdhC (pyruvate dehydrogenase subunit) and pgm 
(phosphoglucomutase) are queried on the PubMLST Neisseria  database, and every unique 
sequence for each locus is assigned a numeric identifier or allele number (69). The PubMLST 
Neisseria database is regularly updated, with each new sequence being assigned a new allele 
number. The unique combination of seven allele numbers (allelic profile) is defined as a 
sequence type (ST) e.g. abcZ [allele no. 35]-adk [24]-aroE [15]-fumC [48]-gdh [6]-pdhc 
[48]-pgm [41], is the allelic profile for N. meningitidis isolates belonging to ST-192. A group 
of related ST’s which contain ≥ 4/7 allele matches is defined as a clonal complex (cc), for 
Neisseria spp. (70).  
 
Multilocus sequence typing however provides limited resolution as this method is based on 
nucleotide variation in only seven genes which are not under selective pressure and remain 
conserved. Meningococci belonging to the same sequence type may exhibit considerable 
variation in other parts of the genome (71), hence MLST is unable to distinguish between 
closely related isolates. Multilocus sequence typing data can therefore be combined with 
sequence data from more rapidly evolving genes to provide more resolution. The combined 
data for serogroup, PorA, FetA, sequence type and clonal complex, form the meningococcal 
strain designation as follows (51): 
 Serogroup: P1. VR1 family-subfamily, VR2 family-subfamily: F family-subfamily: 
ST (cc) 
 Example:  
 Stain designation: NG: P1.7-2,30: F1-2: ST-53 (cc53) 
- NG: non-groupable 
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- P1.7-2,30: PorA VR1 family 7 and subfamily 2, VR2 family 30 
- F1-2: FetA VR family 1 and subfamily 2 
- ST-53: sequence type 53 
- cc: clonal complex 53 
 
1.3.3. The Bacterial Isolate Genome Sequence Database (BIGSdb) platform 
The use of next-generation sequencing enables cost-efficient characterization of 
N. meningitidis and in addition, provides higher resolution than MLST (72;73). The genome 
of N. meningitidis is ~2 million bp, and encodes ~2000 open reading frames (74-76). Since 
2012, the PubMLST Neisseria typing databases have been hosted by the Bacterial Isolate 
Genome Sequence Database (BIGSdb) platform, which is a database system that was 
developed for the flexible storage and analysis of sequencing data of any size, including 
single or multiple genes and whole genome data (77). Following DNA extraction, genome 
sequencing and de novo assembly of short paired-end reads into contiguous sequences 
(contigs) to form draft genomes, the assembled sequences can be uploaded to the respective 
isolate record on the PubMLST Neisseria database and annotated using BIGSdb 
(Supplementary Figure S1) (77). Like the MLST approach which is based on allelic diversity, 
the BIGSdb platform also utilizes the gene-by-gene concept (53;77;78). The prefix ‘NEIS’ is 
allocated to all genes identified in Neisseria spp., followed by a unique numeric gene 
identifier and respective allele number, e.g. NEIS1364 is the unique PubMLST Neisseria 
database identifier for the porA locus, with 201 sequence variants/ alleles being described at 
the time of this study (accessed 11/1/2017). 
 
The BIGSdb platform permits analysis of single or multiple loci which are incorporated into 
functional typing schemes, including metabolism, capsule, genetic information processing, 
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antigen typing, iron acquisition, etc (77). In addition, genome data may be analysed using 
schemes which are extensions of the seven-locus MLST approach, including the ribosomal 
multilocus sequence typing (rMLST) scheme which comprises 53 universal loci encoding 
ribosome protein subunits; and the core genome MLST (cgMLST) scheme comprising 1605 
conserved N. meningitidis loci (72;73). Another typing method implemented by BIGSdb, 
enables Neisseria spp. identification by using a single rMLST locus, more specifically a 413 
bp fragment of the 50S ribosomal protein L6 (rplF) gene (79). The genetic relatedness 
amongst isolates using single or multiple loci may be evaluated using the Genome 
Comparator tool in BIGSdb which constructs phylogenetic trees based on the number of 
differing loci, using the NeighbourNet Algorithm (77).  
 
1.4. Meningococcal pathogenesis  
N. meningitidis is first acquired through respiratory secretions and attaches to the non-ciliated 
mucosal epithelial cells of the human oropharynx, which is the bacterium’s sole ecological 
niche (80;81). The meningococcus then multiplies locally, leading to asymptomatic carriage. 
Parasite-directed endocytosis is initiated by the meningococcus and the phagocytic vacuoles 
pass through the epithelial cell so that the bacterium may enter the extracellular matrix, or 
may migrate back to the cell surface for transmission to another host.  
 
Invasive disease is not part of the normal meningococcal life-cycle, as the bacterium cannot 
be easily transmitted to another host from the bloodstream or cerebrospinal fluid (CSF). 
Reasons for causing IMD are poorly understood, and the meningococcus is thus regarded as 
an ‘accidental pathogen’ (82). Entry into the bloodstream may occur between or through the 
capillary endothelial cells (81). Once in the bloodstream, the meningococcus may multiply 
rapidly resulting in high bacterial loads and meningococcal endotoxin (LPS). Symptoms of 
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meningococcemia include sudden onset of fever, petechial rash leading to purpura fulminans, 
hypotension and shock (83;84). The meningococcus may then cross the brain vascular 
endothelium and invade the meninges and CSF causing symptoms of meningitis, including 
sudden onset of fever, nausea, vomiting, stiff neck, photophobia, headache and disorientation 
(81;83;84). Meningococcemia and meningitis are the most common manifestations of IMD, 
however N. meningitidis may also cause focal infection such as arthritis, pneumonia, 
conjunctivitis, urethritis and pericarditis (83;84).  
 
1.5. Meningococcal carriage  
Meningococcal carriage is an important aspect in understanding disease transmission and 
determining measures for control. This includes planning of immunization programs for 
meningococcal conjugate vaccines which reduce carriage and provide indirect immunity, as 
well as treatment for close contacts (85;86). Meningococcal carriage prevalence in healthy 
individuals was reported to be ~10% in high-income countries (87;88). However, carriage 
rates vary according to age group and were shown to be low during early childhood (under 
five years of age) (86;89). This observation may be due to children less than five-years-old 
having the highest carriage prevalence of Neisseria lactamica, which was shown to inhibit 
meningococcal carriage during nasal-inoculation experiments in young adults (90;91). 
Carriage prevalence peaked during late adolescence (18-26 years) in Europe and the United 
Kingdom (UK), and was associated with social behaviour such as kissing, crowding 
(attendance at night clubs) and smoking (including passive smoke) (87;88;92).  
 
Meningococcal carriage in Africa has been described in the ‘African meningitis belt’ 
(comprising 26 Sub-Saharan countries from Ethiopia to Senegal), which experiences the 
highest annual incidence of IMD in the world. However, results from carriage studies 
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conducted in this region prior to 2009 were not consistent, with carriage prevalences reported 
to be between 2-35%, and peaks observed in variable age groups (93;94). Reasons for the 
observed heterogeneity include sampling different age groups at different times of the year 
and using different swabbing techniques and testing methods (86;94). From 2010 through 
2012, the MenAfriCar consortium conducted cross-sectional surveys and longitudinal 
household surveys to monitor meningococcal carriage and transmission in seven African 
meningitis belt countries; following the implementation of mass vaccination campaigns to 
reduce serogroup A cases, which was most prevalent at the time (86;95). These surveys were 
conducted using standardized methodology and included both the rainy and dry seasons, as 
well as a broad range of age groups. The meningococcal carriage prevalence estimated from 
48490 participants who were sampled across the African meningitis belt during the cross-
sectional surveys, was lower than high-income countries at 3% (86). Risk factors for carriage 
included age (5-14 years), gender (male), season (dry), crowding, smoking within a 
household and indoor kitchen facilities. In contrast to findings from the UK, social behaviour 
was not a risk factor for meningococcal carriage however, the MenAfriCar surveys were 
limited to information regarding the frequency of attendance at social gatherings. The 
carriage prevalence estimated from 980 members of 133 households who were sampled as 
part of the longitudinal household survey was 25%; and the average carriage duration of an 
individual was estimated to be 3.4 months, though persistent carriage of up to 5.8 months was 
observed in 20 individuals (95).  
 
Non-groupable meningococci are frequently associated with meningococcal carriage 
(40;41;86;96) and non-invasive disease (97;98). Approximately 16-46% of meningococci 
from asymptomatic carriers were determined to be unencapsulated (40;41;86). One group of 
unencapsulated meningococci which harboured the capsule null locus (cnl), constituted 46% 
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of N. meningitidis isolates obtained from healthy carriers in the African meningitis belt (86). 
Capsule null meningococci lack the genes required for capsule-specific polysaccharide 
synthesis (region A) and capsular transport (region B and C) within the cps locus, and contain 
the characteristic cnl allele (Figure 2) (40). The cnl is a non-coding DNA fragment of ~113-
368 bp. At the time of this study, 26 unique alleles were defined in the PubMLST Neisseria 
database, with some alleles also identified in N. lactamica and N. gonorrhoeae (Accessed 
11/1/2017) (40). 
 
The capsule null meningococci obtained from asymptomatic carriers belonged to a limited 
number of genetic lineages, including cc53, cc1117, cc198, cc845, cc1136, cc41/44 and 
cc192 (4;40;99). Previous genome data suggested that the cps was acquired through 
horizontal gene transfer into a non-pathogenic ancestor resembling cnl meningococci 
(75;100). Further, cnl meningococci belonging to cc198 or cc1136 were most closely related 
to N. gonorrhoeae and N. lactamica, and showed no signs of recombination in the conserved 
loci which flank the cnl (galE and tex); suggesting that these isolates may resemble 
unencapsulated ancestors of N. meningitidis (101). Alternatively, capsule null meningococci 
may be derived from encapsulated isolates. Genome analysis of a cnl isolate belonging to 
cc53 determined that this isolate was more closely related to encapsulated meningococci, as 
opposed to other cnl isolates belonging to cc198 and cc1136. In addition, the cc53 cnl isolate 
showed evidence of recombination within the galE and tex loci. Further, cc41/44 
predominantly comprises isolates belonging to serogroups B and C, and cnl isolates from this 
clonal complex additionally contained genes in region B of the cps, which are usually absent 
(40). 
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1.6. Disease epidemiology-encapsulated meningococci  
The epidemiology of IMD varies globally and is mostly attributable to encapsulated isolates 
belonging to serogroups A, B, C, W, X and Y (6-13;15). Increased risk of IMD was 
associated with the dry season and age(12;102), previous respiratory disease (103;104), 
crowding (17;105) and host immunosuppression (106-108). In industrialized countries such 
as England and Wales, Europe and the United States of America (USA), the annual IMD 
incidence was reported to be ≤1 case/100 000 population, with most cases being children 
younger than five years of age with disease caused by serogroup B (7;9;13). Invasive disease 
due to serogroups C, W and Y were also observed in industrialized countries, and 
predominantly occurred in adults older than 25 years of age. Serogroup W cases were 
however reported to be increasing in England and Wales (since 2009) and Europe (since 
2011) (9;13;109). From 2000-2002, an increase in serogroup W cases was observed in 
England and Wales amongst Hajj pilgrims (109), a group which has historically been 
associated with increased risk of IMD, predominantly due to serogroups A and W (17). 
Increasing numbers of invasive serogroup Y cases in England and Wales was also reported 
since 2007 (13;110).  
 
The African meningitis belt is characterized by its unique high incidence of IMD, which 
ranges between 10->100 cases/100 000 population (102;111). Reasons for the high disease 
incidence are largely unknown and hypothesized to be associated with extreme 
environmental conditions during the dry season when most outbreaks occur (94;102). The 
high IMD incidence in this region may be related to dust wind from the Sahara which 
damages local mucosal defences, thereby increasing chances of developing IMD upon 
infection. In addition, irritant coughing may facilitate transmission. Prior to the introduction 
of a serogroup A conjugate polysaccharide vaccine in 2010, most cases of IMD were 
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associated with serogroup A (6;11). Disease due to serogroups C (16), W (112) and X (6), 
have since become more prevalent in the belt (11).  
 
Historically, peaks of IMD in South Africa were observed during the 1970’s, 1990 and 1996 
in the Gauteng province, in adult black mine workers; and were due to serogroup A (113). 
During the 1970’s however, serogroup B became prevalent in mixed race children in the 
Western Cape province, and has remained as one of the leading causes of IMD in South 
Africa. In 2005, a peak in IMD incidence due to serogroup W was observed, with most cases 
being reported in the Gauteng province, in children younger than one-year-old (114). In 2015, 
IMD incidence in South Africa was reported to be 0.28 cases/100 000 population (12).  
 
1.7. Disease epidemiology-unencapsulated meningococci 
Despite the high prevalence of unencapsulated meningococci in carriage, cases of IMD by 
this group are uncommon. Fourteen cases of IMD by cnl isolates have been published 
(2;5;115-117), or described in the PubMLST Neisseria database (Table 1). These cases 
occurred in seven countries including Germany (116), Canada (5;115), Burkina Faso (2), 
China (117), Ireland, UK and Austria. Patient demographic information was unknown for 
most cases but where available, cnl meningococci caused disease in both immunocompetent 
and immunocompromised patients; and most patients recovered after treatment with 
antibiotics (2;116;117). One case of IMD which occurred in Canada, in an immunocompetent 
patient was fatal (5). Overall, the 14 invasive cnl isolates belonged to one of five clonal 
complexes including cc198 (n=5), cc1136 (n=4), cc192 (n=3), cc845 (n=1) and cc53 (n=1). 
 
Cases of invasive disease by unencapsulated meningococci were also reported in the USA, in 
immunocompromised twin infants (118). Further, one of the twins developed a second 
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episode of IMD due to the same strain (six months apart), based on identical OMP profiles 
using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The genetic 
mechanism for capsule loss in these isolates was unknown. One case of IMD by an 
unencapsulated isolate belonging to ST-7962 was reported in China, in an immunocompetent 
infant male (119). The loss of capsule expression was due to slipped-strand mispairing in the 
csb gene, in region A of the cps locus. 
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Table 1. Patient demographic data and strain characterization of previously described cases of invasive disease by unencapsulated Neisseria meningitdis isolates. 
Patient 
no. 
Gender 
Age 
(years) 
Underlying 
disease 
Outcome Sequelae Year Country Specimen Strain designation 
Mechanism 
for capsule 
loss 
Reference 
1 Unknown 42 Leukemia Recovered Unknown 2001 Germany Blood NG: P1. 18,25: F5-2: ST-845 (cc845) cnl (116) 
2 Male 12 Unknown Recovered None 2003 Burkina Faso CSF NG: P1.18-11,42: FΔ: ST-192 (cc192) cnl (2) 
3 Male 13 Unknown Recovered None 2003 Burkina Faso CSF NG: P1.18-11,42:FΔ: ST-192 (cc192) cnl (2) 
4 Female 11 Unknown Recovered None 2004 Burkina Faso CSF NG: P1.18-11,42-1: FΔ: ST-192 (cc192) cnl (2) 
5 Female 13 Immunocompetent Fatal N/A 2004 Canada CSF NG: P1.19,13-9: F5-5: ST-198 (cc198) cnl (5) 
6 Female 13 Unknown Unknown Unknown 2006 Canada Blood NG: P1.18,25-1: F5-5: ST-198 (cc198) cnl (115) 
7 Female 7 Immunocompetent Recovered Unknown 2015 China CSF NG: P1. 18,25: F5-70: ST-2146 (cc198) cnl (117) 
8 Unknown Unknown Unknown Unknown Unknown 2013 UK Unknown NG: P1.18,25-14: F-ND: ST-823 (cc198) cnl PubMLST  
9 Unknown Unknown Unknown Unknown Unknown 2012 Austria Unknown NG: P1.18,25-15: F5-5: ST-823 (cc198) cnl PubMLST 
10 Unknown Unknown Unknown Unknown Unknown 2015 Ireland Unknown ND: P1.18-4,25-31: F3-9: ST-1136 (cc1136) cnl PubMLST 
11 Male 10 Unknown Unknown Unknown 2009 Canada Blood NG: P1.18-4,25: F4-1: ST-1136 (cc1136) cnl PubMLST 
12 Unknown Unknown Unknown Unknown Unknown 2015 Ireland Unknown NG: P1.18-4,25-31: F3-9: ST-1136 (cc1136) cnl PubMLST 
13 Unknown Unknown Unknown Unknown Unknown 2010 UK Unknown NG: P1.12-17,4-1: F3-6: ST-1136 (cc1136) cnl PubMLST 
14 Unknown <1 Unknown Unknown Unknown 2012 Ireland Unknown NG: P1.7,30: F1-6: ST-53 (cc53) cnl PubMLST 
15 Male <1 C6 deficiency Recovered None 1986 USA CSF NG: P1.ND: F-ND: ND (-) Unknown (118) 
15 Male <1 C6 deficiency Recovered None 1986 USA Blood NG: P1.ND: F-ND: ND (-) Unknown (118) 
16 Male <1 C6 deficiency Recovered None 1986 USA CSF NG: P1.ND: F-ND: ND (-) Unknown (118) 
17 Male <1 Immunocompetent Recovered Unknown 2009 China CSF NG: P1.7-2,14: F4-21: ST-7962 (-) 
Slipped-
strand 
mispairing 
(119) 
Abbreviations: C6, sixth complement component; N/A, not applicable; NG, nongroupable; P1, PorA; F, FetA; ST, sequence type; cc, clonal complex; Δ, gene deletion; ND, 
not defined; cnl, capsule null locus; PubMLST, PubMLST Neisseria database (http://pubmlst.org/neisseria/) 
19 
1.8. Vaccines 
The first polysaccharide vaccines were developed during the 1960’s, and targeted 
N. meningitidis serogroups A or C (120). Polysaccharide vaccines were developed in bivalent 
(A and C), trivalent (A, C and W) and quadrivalent (A, C, W and Y) formulations (121). 
However, meningococcal capsular polysaccharide molecules are T-cell-independent antigens 
which elicit poor immunologic memory and provide limited protection; and repeated doses 
lead to immunologic hyporesponsiveness (122). In addition, polysaccharide vaccines are 
poorly immunogenic in children younger than five years of age (123;124). Polysaccharide 
vaccines were also unable to eradicate meningococcal carriage (125). These drawbacks 
prompted the development of monovalent (A or C) and quadrivalent (A, C, W and Y) 
formulations of conjugate polysaccharide vaccines.  
 
Meningococcal conjugate vaccines elicit a T-cell dependent immune response, and therefore 
provide lasting protection (126). In addition, conjugate vaccines induce immunity in children 
younger than five-years-old and adults (127;128); and provide indirect immunity by reducing 
meningococcal carriage (86;129). The meningococcal serogroup C-diphtheria toxoid vaccine 
(MCC) was the first meningococcal conjugate vaccine to be developed and licensed, and was 
introduced into the routine infant immunization schedule for individuals younger than 19 
years in the UK, in 1999 (129). The MCC vaccine was implemented in response to increasing 
numbers of serogroup C IMD cases in the UK (130). According to recent data from England 
and Wales (2015/2016), the number of IMD cases due to serogroup C was reduced by 96% 
since vaccine implementation (13). Conjugate serogroup C vaccines have since been 
implemented in routine immunization programmes in European countries, Canada, New 
Zealand and Australia (121). 
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The success of the MCC vaccine prompted the development of a low-cost monovalent 
serogroup A polysaccharide-tetanus toxoid vaccine (MenAfriVac™, Serum Institute of India, 
Pune, India), as part of the Meningitis Vaccine Project (131). Mass vaccination campaigns 
were initiated in 2010, and targeted 217 million people living in 15 African meningitis belt 
countries. Although the incidence of IMD due to serogroup A was significantly reduced, 
cases of disease due to serogroups C, W and X were also reported in African meningitis belt 
countries, emphasizing the need to develop a low-cost multivalent vaccine (11).  
 
In 2015, the quadrivalent conjugate meningococcal vaccine (A, C, W and Y) was introduced 
into the national immunization programme for adolescents in England and Wales, due to the 
increase in serogroup W cases (132). Quadrivalent conjugate meningococcal vaccines were 
also licensed for use in adolescents in the USA (133). Quadrivalent polysaccharide vaccines, 
Mencevax ACW135Y® (GlaxoSmithKline, Belgium, Europe) and Menomune®–A/C/Y/W-
135 (Sanofi Pasteur Inc., Pennsylvania, USA), have been available in South Africa since 
2003 and 2007, respectively (107). The quadrivalent conjugate meningococcal vaccine, 
Menactra® (Sanofi Pasteur Inc., Pennsylvania, USA) was recently introduced in 2014 (134). 
Meningococcal vaccines are however not routinely used in South Africa as public health 
priorities are directed towards high burden diseases such as HIV and tuberculosis, but are 
available privately and are recommended for individuals at high risk of acquiring IMD, 
including patients with terminal complement deficiencies and anatomical or functional 
asplenia (107;134). Other high risk groups include travellers to areas at increased risk of 
epidemics, Hajj pilgrims, university students, infants and children.  
 
Serogroup B is a major cause of IMD in industrialized countries. The serogroup B capsule is 
composed of α2→8 linked N-acetylneuraminic acid, which is similar to the polysialic 
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structures in human brain tissue, and may therefore act as an autoantigen (135;136). 
Meningococcal OMP’s are immunogenic and therefore form the basis of serogroup B 
vaccines, which were initially developed to specifically control outbreak strains in Norway 
(137), Chile (138), Cuba (139) and New Zealand (140). The strain coverage of these OMP 
vaccines were however limited, considering that meningococcal OMP’s are highly variable 
due to selection pressure.  
 
Novel conserved surface antigens to develop a broad range serogroup B vaccine were later 
identified from the genome of a virulent serogroup B strain (MC58), in a process is called 
‘reverse vaccinology’ (141). The antigens were recombinantly expressed in Escherichia coli, 
purified and used to immunize mice, which were monitored for an immunological response. 
Antigens for vaccine development were selected based on their potential to induce broad 
protection against a variety of serogroup B strains (142). The Bexsero® or 4CMenB vaccine 
(Novartis Vaccines, Sienna, Italy), contains fHbp (variant 1.1), NadA (peptide 8, variant 2/3) 
and NHBA (peptide 2) (143;144). The Bexsero® vaccine also contains outer membrane 
vesicles prepared from N. meningitidis strain NZ98/254 which expresses the PorA antigen 
P1.4 (144). The Bexsero® vaccine was approved for use in 37 countries including Australia, 
USA, EU/EEA countries and Canada (145). Additionally, the bivalent fHbp vaccine 
Trumenba® (Pfizer, New York, USA) which contains both subfamily A and B variants 
(peptides A05 and B01) was licensed for use in the USA, in 2014 (146;147). Bexsero® and 
Trumenba® were also recommended for patients at risk of serogroup B disease including 
those with persistent complement deficiency, in the USA (148). Serogroup B vaccines are 
however not yet available in South Africa.  
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1.9. Virulence  
According to MLST data, meningococci are genetically diverse, with 12897 ST’s belonging 
to 52 clonal complexes being defined on the PubMLST Neisseria database (Accessed 
14/04/2017). However, most cases of IMD are caused by only a few clonal complexes or 
‘hypervirulent lineages’ (149;150). Conversely, meningococci isolated from asymptomatic 
carriers are more diverse, and belong to clonal complexes which are infrequently associated 
with invasive disease (151;152). Despite the lack of the polysaccharide capsule, 
unencapsulated meningococci which are predominantly associated with carriage, were 
reported in cases of IMD in apparently healthy patients (5;117;119). Further, invasive cnl 
meningococci belonging to cc192 were shown to resist serum killing, and were comparable to 
an encapsulated serogroup B strain (2). These findings therefore imply that non-capsular 
virulence mechanisms may also play a role in the invasive potential of N. meningitidis. 
Comparative genome hybridization and whole genome sequencing which have been used to 
differentiate between commensal and pathogenic Neisseria spp. (153-155), and more 
specifically commensal and pathogenic meningococci (71;75;156-159); have failed to define 
a pathogenome. Although mobile genetic elements have been significantly associated with 
invasive meningococci, their contribution to meningococcal virulence is unclear (71;156).  
 
1.10. Diagnosis  
In South Africa, a ‘possible case’ of IMD is defined as a clinical diagnosis of meningitis or 
septicemia which may be due to N. meningitidis, however other diagnoses are also considered 
(107). A ‘probable case’ is defined as the clinical diagnosis of meningitis and/or septicemia 
with N. meningitidis being the most likely cause of disease. These definitions differ to those 
used in other parts of the world for instance, in Europe, a probable case is defined as any 
individual meeting the clinical criteria for IMD with an epidemiological link (160); whilst 
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laboratory detection of N. meningitidis using latex agglutination is required to classify a 
probable case of IMD in the USA (161). The definition of a ‘confirmed case’ of IMD in 
South Africa is similar to those used in the USA and Europe, and includes the identification 
of N. meningitidis from a normally sterile site specimen (blood, CSF, pleural fluid) by 
culture, Gram’s stain and/or antigen detection-latex agglutination result, or a positive PCR 
result (107;160;161). The use of genotypic assays are particularly important in cases where 
antibiotic therapy was administered prior to specimen collection, which may result in culture-
negative specimens. Real-time PCR assays which are sensitive, specific and allow for rapid 
diagnosis, were developed for the identification of N. meningitidis by detection of the 
superoxide dismutase (sodC) gene, which is able to detect both encapsulated and 
unencapsulated meningococci (162). Meningococci which are potentially encapsulated may 
be indicated by detection of the capsule transport gene (ctrA), and further characterized using 
serogroup-specific targets (32). 
 
1.11. Treatment and public health response in South Africa 
In South Africa, all suspected cases of IMD are immediately notified to a local health 
authority. Probable and confirmed cases prompt a public health response which includes the 
identification of close contacts and administering post-exposure chemoprophylaxis, and 
identifying other cases of IMD in the same area which may indicate a cluster of disease 
(107). Intravenous benzyl penicillin is the first drug of choice for proven meningococcal 
septicemia and meningitis cases for 5-7 days, followed by a single-dose of ciprofloxacin or 
two-day course of rifampicin to eradicate carriage (107;163). Ceftriaxone or cefotaxime were 
however recommended as the empiric therapy for suspected bacterial meningitis. 
Ciprofloxacin, ceftriaxone or rifampicin are administered to close contacts of confirmed and 
probable cases within 24 hrs of identification of the index case, but still may be effective 10 
24 
days after exposure. A ‘close contact’ is regarded as an individual who has had prolonged 
contact with respiratory secretions within seven days illness onset of the case e.g. persons 
within a household (107). In addition, prophylactic treatment is administered to individuals 
who have had transient close contact with the case and were directly exposed to large 
respiratory droplets within 10 days of illness onset e.g. in health-care settings whereby 
procedures such as mouth-to-mouth resuscitation were performed. Although not routinely 
practiced, life-long treatment with penicillin is recommended for patients with complement 
deficiency to prevent recurrent episodes of IMD (108).  
 
1.12. Aim 
To characterize invasive non-groupable N.meningitidis isolates obtained through the South 
African national laboratory-based surveillance, from January 2003 through December 2013.  
 
1.13. Objectives 
 To describe cases of invasive disease caused by non-groupable N. meningitidis 
in South Africa 
 To phenotypically characterize the invasive non-groupable meningococci 
using standard microbiological methods and serological serogrouping  
 To phenotypically confirm the presence or absence of a capsule using TEM 
 To determine the minimum inhibitory concentrations (MIC) of each non-
groupable isolate to penicillin, chloramphenicol, rifampicin, ciprofloxacin, 
trimethoprim-sulfamethoxazole and ceftriaxone 
 To determine the genetic mechanism for capsule loss by analysis of the cps 
locus using real-time PCR and whole genome data 
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 To describe the molecular characteristics of each non-groupable isolate using 
real-time PCR, rplF typing and examining the translated protein products 
encoded by the porA and fetA loci from genome data. Sequence type and 
clonal complex were also determined   
 To determine the phylogenetic relatedness of the South African cnl 
meningococci to other cnl meningococcal genomes which were publically 
available on the PubMLST Neisseria database, using seven-locus MLST, 
rMLST and cgMLST 
 To identify non-capsular mechanisms for meningococcal virulence by 
comparing previously described putative virulence genes (n=117) in invasive 
and carriage cnl N. meningitidis genomes available on the PubMLST 
Neisseria database 
 To determine the effect of protein-based serogroup B vaccines (Bexsero® and 
Trumenba®) on cnl meningococci in silico, by examining the translated 
protein products of fHbp, nadA and nhba
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CHAPTER TWO: MATERIALS AND METHODS  
2.1. Meningococcal surveillance, 2003-2013 
National laboratory-based surveillance for IMD in South Africa was established in 1999 
(164) and was enhanced in 2003 through the Group for Enteric, Respiratory and Meningeal 
Disease Surveillance (GERMS-SA) (114). Approximately 200 microbiology laboratories 
from the private and public sector submitted meningococcal isolates and/or clinical 
specimens together with patient demographic information to the National Institute for 
Communicable Diseases (NICD) for confirmation and characterization. Additional 
information such as underlying disease, HIV status, antiretroviral use and patient outcome 
were also sought from hospital records. A case of IMD was defined as the identification of 
N. meningitidis from a normally sterile site specimen by culture, Gram’s stain and/or antigen 
detection-latex agglutination result, or a positive PCR result. If a case of IMD was reported 
≥21 days after the first episode, it was regarded as a new case.  
 
2.2. Bacterial culture and characterization 
At the NICD, N. meningitidis identification was confirmed using standard microbiological 
methods including, culture on 5% horse blood agar (Diagnostic Media Products (DMP), 
Johannesburg, South Africa) (24 hr, 5% CO2, 37°C), oxidase test and Gram’s stain (19). Pure 
meningococcal cultures (24 hr, 5% horse blood agar) were stored in 1 ml of 10% skim milk 
(DMP, Johannesburg, South Africa) at -70°C.  
 
Phenotypic serogrouping was performed by preparing a milky suspension of single colonies 
(24 hr, 5% horse blood agar) in 0.5 ml 10% formal saline, and mixing 10 µl of the cell 
suspension with 10 µl of individual capsule-specific antibodies (Remel Biotech Ltd, 
Dartford, UK) to detect serogroups A, B, C, W, X or Y, on a glass slide. The antigen-
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antibody suspensions and 10 µl of the formal saline-cell suspension with no antibody 
(control), were shaken for 2 minutes (min) and observed for agglutination. A positive 
reaction was characterized as a negative saline control and agglutination with one capsule-
specific antibody. Isolates were reported as non-groupable if agglutination was observed in 
the saline control (autoagglutination), or if agglutination occurred with more than one 
monoclonal antibody (polyagglutination), or if no agglutination was observed in the saline 
control and antisera (non-reactive/ negative) (36).  
 
Real-time PCR was used to confirm phenotypic identification and slide agglutination 
serogrouping results. DNA was extracted from a single colony (24 hr, 5% horse blood agar) 
which was added to 200 µl of nuclease free water (Anatech Analytical Technology, 
Michigan, USA), and boiled at 95°C for 10 min. The boiled suspensions were briefly 
centrifuged and tested using real-time PCR to detect ctrA and serogroups A (csaB), B (csb), 
C (csc), W (csw), X (csxB), and Y (csy) (Supplementary Table S1) (32). From 2003 through 
2013, we identified five IMD isolates which were negative for ctrA and six serogroups. 
N. meningitidis identity was reconfirmed using API-NH (bioMérieux, Marcy-l'Étoile, 
France), and real-time PCR to detect the superoxide dismutase (sodC) gene (Supplementary 
Table S1) (162). All real-time PCR assays incorporated the following cycling conditions: 
50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 seconds (sec) and 60°C for 1 min; 
using the Applied Biosystems 7500 Fast real-time PCR platform (Applied Biosystems, 
California, USA). The five non-groupable isolates were further characterized by whole 
genome sequencing.  
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2.3. Antimicrobial susceptibility testing 
Minimum inhibitory concentrations for penicillin, chloramphenicol, rifampicin, 
ciprofloxacin, trimethoprim-sulfamethoxazole and ceftriaxone were determined using the E-
test® (bioMérieux, Marcy-l'Étoile, France) method. Briefly, 3 ml saline suspensions of 1-2 x 
108 CFU/ml were prepared from 18-24 hr colonies on 5% horse blood agar, and inoculated 
onto Mueller-Hinton agar supplemented with 5% defibrinated sheep blood (DMP, 
Johannesburg, South Africa) to form an even lawn of growth. The inoculated plates were 
dried for 15 min before placing a maximum of two E-test® strips per plate, followed by 
incubation for 24 hrs at 37°C and 5% CO2. After incubation, MIC’s were interpreted using 
Clinical and Laboratory Standards Institute guidelines (165).  
 
2.4. DNA extraction and quantification for genome sequencing 
The Wizard® Genomic DNA Purification Kit (Promega, Madison, USA) was used to extract 
DNA from the invasive South African non-groupable isolates for genome sequencing. In 
summary, a sweep of overnight culture (3-5 µl) was suspended in 600 µl of Nuclei Lysis 
Solution and incubated at 80°C for 5 min. After cooling to room temperature, 3 µl of RNase 
Solution was added to the cell lysate, mixed by inversion and incubated at 37°C for 30 min. 
The lysate was cooled to room temperature and 200 µl of Protein Precipitation Solution was 
added. The suspension was vortexed for 20 sec, incubated on ice for 5 min and centrifuged at 
13,000 x g for 3 min. The supernatant was transferred to a sterile 1.5 ml microtube, to which 
600 µl of room temperature isopropanol (Sigma Aldrich, France, Europe) was added, and 
gently mixed. The suspension was centrifuged at 13,000 x g for 2 min and the supernatant 
was discarded. The pellet was washed with 600 µl of 70% ethanol (Sigma Aldrich, France, 
Europe), and centrifuged at 13,000 x g for 2 min. The ethanol was carefully aspirated and the 
pellet was allowed to dry for 10-15 min, before being re-suspended in 100 µl of DNA 
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Rehydration Solution. The DNA extracts were incubated overnight at 4°C prior to 
quantification, and thereafter stored at -20°C.  
 
The DNA extracts were quantified using the Qubit® 2.0 fluorometer (Invitrogen, Oregon, 
USA) and Qubit® dsDNA BR assay kit. A mastermix was prepared from 199 µl BR buffer 
and 1 µl BR reagent per sample, and 195 µl of the mixture was added to 5 µl of extracted 
DNA. The DNA-mastermix suspension was incubated at room temperature for 2 min before 
quantification.  
 
2.5. Genome sequencing, assembly and annotation 
Library preparation was performed using the Nextera XT DNA Library Prep Kit (Illumina, 
California, USA) according to manufacturer’s instructions, and sequenced using the Illumina 
platform. The reads were de novo assembled using Velvet (version 1.2.08) combined with the 
VelvetOptimiser script (version 2.2.4) to a draft level (166;167). The minimum output 
contiguous assembly size was set to 100 bp with scaffolding turned off and all other 
parameters were set as default. No read trimming was performed. The sequence assemblies 
were uploaded into PubMLST.org/ Neisseria. Annotation of the genomes was performed 
using the PubMLST Neisseria database, which implements the BIGSdb platform and are 
publically available [PubMLST: 29306, 29312, 37616, 41860 and 41961] (77). Additionally, 
Illumina sequencing was performed for four non-groupable cc192 isolates from Burkina Faso 
(two carriage and two invasive) at Public Health England, Colindale [PubMLST: 35416, 
35417, 35418 and 35419] (Supplementary Table S2) (2;4). Sequence reads were also 
deposited in the European Nucleotide Archive (ENA) (http://www.ebi.ac.uk/ena), for the 
South African [accession: ERR519863, ERR519789, ERR519785, ERR1805704 and 
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ERR1805705] and Burkina Faso isolates [accession: ERR903637, ERR903631, ERR903647 
and ERR903634].  
 
2.6. Identification of capsule null isolates 
Genome Comparator, a BIGSdb tool, was used to verify PCR negative results for serogroups 
A, B, C, X, W and Y, and to determine if isolates were serogroups E, H, I, K, L or Z; or 
harboured a cnl allele (PubMLST Neisseria database locus identifier: NEIS2743) (24;40;77). 
Capsule regions A and C were further investigated to confirm the presence of the cnl allele 
using CLC Genomics Workbench version 7.5.1 (CLC bio, Aarhus, Denmark). Additional 
non-groupable N. meningitidis genomes harbouring a cnl allele were identified in the 
PubMLST Neisseria database at the time of this analysis, for phylogenomic comparison with 
the South African isolates (Supplementary Table S2) (Accessed: 01 July 2016). In addition, 
genes flanking the cnl allele, namely, galE (NEIS0048) and tex (NEIS0059), were compared 
in all isolates in the PubMLST Neisseria database. 
 
2.7. Strain typing of capsule null isolates 
Species identity was confirmed in silico by the presence of sodC (NEIS1339) and analysis of 
a 413 bp fragment of the 50S ribosomal protein L6 (rplF,  NEIS0147) (79). Multilocus 
sequence type (ST) and peptide typing fragments for porin A (PorA) variable regions (VR) 1 
and 2, ferric enterochelin receptor (FetA) VR, factor H-binding protein (fHbp), neisserial 
adhesin A (NadA) and neisserial heparin-binding antigen (NHBA), were identified from the 
whole genome data (51;57;58;60).  
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2.8. Phylogenomic comparison of capsule null meningococci 
The Genome Comparator tool was used to construct phylogenetic networks to assess the 
relationships between the South African cnl isolates and additional cnl genomes. Isolates 
were compared using seven MLST genes, 53 rMLST genes and 1605 core genes [cgMLST 
scheme v1.0] (69;72;73). The distance matrices were visualized as Neighbor-net phylogenies 
and annotated using SplitsTree version 4.13.1 (168). The degree of relatedness between 
isolates was quantified by calculating the mean number of differing core loci between isolates 
and statistical significance was determined using the Fisher’s exact test (p<0.05). Loci which 
were absent in at least one isolate or incomplete as a result of being situated at the end of a 
contig, were excluded from analysis. Functional annotations for variable core loci were 
determined using the PubMLST Neisseria database.  
 
2.9. Identification of genetic markers for potential differentiation of carriage and 
invasive capsule null meningococci 
The Genome Comparator tool was used to examine 117 previously defined putative virulence 
loci, in 51 carriage and 14 invasive capsule null isolates with known epidemiology 
(Supplementary Table S3) (75). The ST-192 (cc192) isolates from Malawi were not included 
in the analysis as genome data were not available on the PubMLST Neisseria database at the 
time of analysis (22 December 2016). A mutually exclusive gene or allele was defined as 
being present in all isolates in one group (carriage or invasive) and absent in the other. 
 
2.10. Transmission electron microscopy 
As part of a validation to visualize encapsulated Gram-positive and Gram-negative bacteria, 
encapsulated N. meningitidis control isolates belonging to serogroups A (ATCC®-13077™), 
B (ATCC®-13090™), W (ATCC®-35559™) and Y (ATCC®-35561™), and an 
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unencapsulated N. lactamica strain (ATCC-23970™); were visualized using previously 
described TEM methods which were modified as stipulated in Birkhead et al. (1). These 
methods included negative staining (1), simultaneous glutaraldehyde-osmium tetroxide 
fixation adapted from Frank et al. (169), pre-incubation with a cationic dye such as 
ruthenium red or alcian blue pyridine variant and en bloc staining, adapted from Hayat (170); 
L-lysine acetate fixation with a cationic dye such as ruthenium red or alcian blue (pyridine or 
8XG variant) adapted from Jacques and Graham (171), Erlandsen et al. (172) and 
Hammerschmidt et al. (44). The L-lysine acetate fixation with alcian blue (pyridine variant) 
stained capsular material from all encapsulated N. meningitidis controls and did not indicate 
capsule around N. lactamica (although staining of extracelluar material between cells was 
observed), and was therefore used to visualize the South African non-groupable isolates. 
 
Briefly, polytop vials were used to punch out agar disks with single colonies (24hr, 5% horse 
blood), which were fixed using a primary fixative consisting of 2% methanol-free 
formaldehyde, 2.5% glutaraldehyde, 1.55% L-lysine acetate and 0.15% alcian blue pyridine 
variant for 20 min, on ice. The agar disks were then washed with chilled dyed buffer prepared 
from 0.1 M sodium cacodylate buffer (deionised distilled water, 0.09 M sucrose, 0.01 M 
CaCl2.2H2O and 0.01 M MgCl2.6H2O) and 0.15% alcian blue to a final pH of 7.15; fixed on 
ice for 3 hrs using the primary fixative without 1.55% L-lysine acetate, and washed with 
chilled dyed buffer three times (20 min per rinse). Post-fixation was carried out by incubating 
the samples in 1% osmium tetroxide in dyed buffer for 1 hr on ice. After five rinses with 
chilled dyed buffer (20 min per rinse), the samples were dehydrated using a graded chilled 
ethanol series (10%, 20%, 35%, 50% and 70%) at 30 min intervals. After the 10% ethanol 
dehydration step, the colonies were scraped off the agar and placed into a 1.5 ml Eppendorf 
tube, which was centrifuged at 500 x g, 4°C for 15 min between subsequent dehydration 
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steps. The samples were incubated overnight on ice in 70% ethanol, followed by ethanol 
rinses at 90% (x 1) and 100% (x 4). The cells were then infiltrated on ice with 1:1 ethanol: 
London Resin White (medium, Agar Scientific, Stansted, UK) for 4 hrs, 1:2 ethanol: resin 
overnight, three changes of pure resin at 12 hr intervals; with centrifugation steps not 
exceeding 3,000 x g for 40 min between changes. The cells were transferred to gelatine 
capsules together with pure resin and polymerized for 48 hrs at 62°C. The capsules were 
sectioned into 70 nm sections using a Leica EM UC6 ultramicrotome (Leica-microsystems, 
Wetzlar, Germany) and stained with 4% uranyl acetate for 5 min. The ultrathin sections on 
0.25% formvar-coated copper slot-grids were viewed at 80 kV on a BioTwin Spirit 
transmission electron microscope (FEI Company, Oregon, USA) with a Quemesa CCD 
camera (Olympus, Germany, Europe). N. meningitidis serogroup W strain (ATCC-35559™) 
was used as an encapsulated control, whilst N. lactamica strain (ATCC-23970™) was used as 
an unencapsulated control.  
 
2.11. Ethics and consent to participate  
GERMS-SA surveillance (M140159) and project-specific (M150349) ethics were approved 
by the Human Research Ethics Committee of the University of the Witwatersrand. Details of 
informed consent were included in the national-laboratory based surveillance program 
(protocol number: M140159). Briefly, written informed consent was obtained from parents or 
legal guardians if participants/ patients were minors; and assent was obtained from minors 
who were old enough to understand.  
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CHAPTER THREE: RESULTS 
3.1. Identification and characterization of invasive capsule null meningococci 
From 2003 through 2013, 4770 cases of IMD were reported, with viable isolates available for 
2988 (63%) cases. We identified five N. meningitidis isolates that were phenotypically and 
genotypically negative for serogroups A, B, C, W, X and Y. The isolates were also ctrA PCR 
negative but were sodC PCR positive. Transmission electron microscopy confirmed the 
absence of a polysaccharide capsule (Figure 3). 
 
One of the five isolates, 37616, did not contain a cnl allele, belonged to ST-11147 (cc41/44) 
and contained capsule transport genes in region B (ctrE and ctrF) and lipopolysaccharide 
synthesis genes (rfbA-C and galE) in region D of the cps locus. All region A genes except for 
ctrG were absent, as well as ctrA from region C. The remaining four ctrA negative isolates 
lacked genes in regions A and C (ctrA-D) and contained a 114 bp cnl allele. Further, these 
isolates contained all region D lipopolysaccharide synthesis genes and lacked region B genes. 
The locus was identified as cnl allele 12 in isolate 29312, and cnl allele 2 in isolates 29306, 
41860 and 41961 (Figure S2) (40). Isolates 29306, 41860 and 41961 lacked the fetA locus. 
The finetypes for the four cnl isolates were as follows: isolate 29312 was NG: P1.7-2,30: F1-
2: ST-53 (cc53), and isolates 29306, 41860 and 41961 were NG: P1.18-11,42-2: FΔ: ST-192 
(cc192).
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Figure 3. Transmission electron micrographs showing the presence of surface capsular polysaccharide for A) Neisseria meningitidis serogroup 
W (ATCC 35559) and B) absence of capsule for Neisseria lactamica (ATCC 23970). Clinical isolates from South Africa are depicted in C) 
29312 D) 29306 E) 41961 and F) 41860. The scale bars represent 200 nm. 
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3.2. Clinical case descriptions 
The four invasive cnl meningococi were isolated from three patients, including one patient 
with recurrent meningococcal disease (Table 2). All three patients responded well to 
antibiotic therapy and subsequently recovered from their IMD episodes. The four cnl isolates 
were susceptible to all antimicrobials except for trimethoprim-sulfamethoxazole.  Additional 
information regarding vaccination status and long-term complications for all three patients 
was sought, but unfortunately these data were not available. 
 
The first patient, an adult male, was previously diagnosed with multiple chronic illnesses 
including diabetes mellitus, hypertension, osteoarthritis and chronic obstructive pulmonary 
disease. He was a smoker, morbidly obese and had a right lower lobe lobectomy in 2003 due 
to damage from a previous tuberculosis infection. In 2006, he was diagnosed with empyema 
and N. meningitidis was cultured from the pleural fluid (isolate 29312). The second patient, 
an adolescent male, was diagnosed with meningococcal meningitis in 2010 (isolate 29306). 
Unfortunately, information regarding underlying disease conditions and the severity of 
disease could not be obtained. The third patient was a male child with deficiency of the sixth 
complement component (C6). In 2011, he was diagnosed with meningitis (isolate 41961), 
however, eight months later, in 2012, he presented with fever and disorientation and 
N. meningitidis was isolated from the blood (isolate 41860). He was prescribed life-long 
treatment with penicillin. His mother received a dose of the quadrivalent conjugate vaccine 
(Menactra®) in 2015. 
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Table 2. Patient demographic information and phenotypic and genotypic characteristics of four invasive capsule null (cnl) Neisseria meningitidis 
isolates identified through national laboratory-based surveillance in South Africa, 2003-2013. 
 
Characteristic     
 
  
Patient  1  2  3 (Episode 1)a 3 (Episode 2)a 
Gender  Male Male Male Male 
Age category (years) 45-64 15-24 5-9 5-9 
HIV status Negative Unknown Negative Negative 
Antiretroviral use Not applicable Unknown Not applicable Not applicable 
Underlying disease 
Diabetes mellitus, 
COPD Unknown C6 deficiency C6 deficiency 
Year of disease presentation 2006 2010 2011 2012 
Province  Western Cape Gauteng Free State Free State 
Patient outcome Recovered Recovered Recovered Recovered 
Specimen type Pleural aspirate CSF CSF Blood 
     Isolate  
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Minimum Inhibitory 
Concentrations (µg/ml) 
    Penicillin G  0.032 (S) 0.064 (S) 0.064 (S) 0.047 (S) 
Ceftriaxone  ≤ 0.002 (S) ≤ 0.002 (S) ≤ 0.002 (S) ≤ 0.002 (S) 
Trimethoprim-  
sulfamethoxazole 8 (R) 12 (R) 3 (R) 3.8 (R) 
Chloramphenicol  0.75 (S) 1 (S) 1 (S) 0.38 (S) 
Rifampicin  0.008 (S) 0.032 (S) 0.064 (S) 0.032 (S) 
Ciprofloxacin  0.008 (S) 0.008 (S) 0.006 (S) 0.006 (S) 
Molecular characterization 
    cnl allele (NEIS2743) 12 2 2 2 
Strain designation 
 
NG: P1.7-2,30: F1-2: 
ST-53 (cc53) 
NG: P1.18-11, 42-2: FΔ: 
ST-192 (cc192) 
NG: P1.18-11, 42-2: FΔ: 
ST-192 (cc192) 
NG: P1.18-11, 42-2: 
FΔ: ST-192 (cc192) 
Genome information 
    Approx genome size (bp) 2,104,685 2,040,849 1,995,940 2,003,633 
No. contigs 119 111 447 489 
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Neisseria PubMLST.org 
identification number 29312 29306 41961  41860 
a Patient three presented with two episodes of invasive meningococcal disease in 2011 (episode 1) and 2012 (episode 2, 8 months later), 
respectively. He was diagnosed with deficiency of the sixth complement component (C6). 
Abbreviations: COPD, chronic obstructive pulmonary disease; C6, sixth complement component; CSF, cerebrospinal fluid; S, susceptible; R, 
resistant; NG, non-groupable; P1, PorA; F, FetA; ST, sequence type; cc, clonal complex; Δ, gene deletion. 
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3.3. Comparison of South African and other capsule null meningococcal genomes 
The four South African isolates were compared to 89 cnl meningococcal genomes available 
on the PubMLST Neisseria database, including four cc192 Burkina Faso isolates that were 
sequenced as part of this study (Supplementary Table S2). The remaining 85 isolates 
belonged to seven clonal complexes including cc53 (n=48), cc198 (n=13), cc41/44 (n=8), 
cc1136 (n=6), cc192 (n=6), cc1117 (n=3) and cc213 (n=1). All cnl meningococci (n=93) 
harboured fHbp and nhba, but lacked nadA. Phylogenetic analysis of 53 ribosomal MLST 
(rMLST) loci clustered the 93 cnl isolates by clonal complex (data not shown). Data for 646 
of 1605 core genome MLST (cgMLST) loci were incomplete and were excluded from further 
analysis. Phylogenetic analysis of the remaining 959 of 1605 cgMLST loci in all cnl isolates 
(n=93), demonstrated clustering by clonal complex (Figure 4). Isolates within each respective 
clonal complex contained identical cnl alleles, except for cc41/44 which contained alleles 2 
or 12; and cc192 which contained alleles 2 or 3. Additional analysis of 117 putative virulence 
loci in 51 carriage and 14 invasive cnl isolates including those from South Africa, determined 
no mutually exclusive loci or alleles (data not shown). Most putative virulence loci were 
identified in both carriage and invasive isolates (97/117), and the remaining 20 loci were 
absent in all 65 isolates. 
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Figure 4. Phylogenetic analysis of 959 of 1605 core genes (cgMLST) genes in capsule null Neisseria 
meningitidis isolates (n=93) belonging to clonal complexes (cc) 53 (n=49), cc198 (n=13), cc192 
(n=13), cc1136 (n=6), cc41/44 (n=8), cc1117 (n=3) and cc213 (n=1). Individual cgMLST phylogenies 
are also illustrated for cc53 and cc192. Clusters are highlighted in grey and the invasive South African 
isolates are represented by red nodes. Isolates 41860 and 41961 were from recurrent invasive disease 
episodes in the same patient. The scale bars represent the number of variant loci. All genomes are 
available on the pubmlst.org/neisseria website. 
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3.3. Clonal complex 53 
At the time of analysis, in addition to isolate 29312, complete genome data were available for 
48 non-groupable cc53 isolates in the PubMLST Neisseria database. Forty-seven were 
carriage isolates from either the UK (n=31), Czech Republic (n=9), Italy (n=6) or Germany 
(n=1), and one was an invasive isolate from Ireland in 2012. The cc53 isolates (n=49) 
belonged to one of six STs, namely, ST-53 (n=42), ST-2441 (n=3), ST-123 (n=1), ST-124 
(n=1), ST-11167 (n=1) or ST-11133 (n=1). All cc53 isolates harboured cnl allele 12 flanked 
by galE allele 16, and one of five tex alleles (5, 787, 222, 788 or 969). GalE allele 16 was 
present in one cc41/44 isolate, also harbouring cnl allele 12. All cc53 isolates possessed 
alleles 24 or 102 for the fHbp family 2/subfamily A antigen. The NHBA allele 65 (peptide 
58) was present in all of the cc53 isolates, except the South African isolate which harboured 
allele 149 (peptide 191). 
 
Using seven-locus MLST, the cc53 isolates were resolved into six clusters (data not shown). 
Ribosomal MLST further resolved these isolates into 21 clusters and the South African isolate 
had a unique rMLST profile (data not shown). Core genome MLST indicated that the South 
African isolate was more closely related to two carriage isolates circulating in the Czech 
Republic in 1993, than to carriage isolates from the UK, Italy and Germany, and the invasive 
isolate from Ireland (Figure 4). Overall, 221/959 (23%) cgMLST loci had identical nucleotide 
sequences amongst the cc53 isolates (n=49).  
 
3.4. Clonal complex 192 
Genome data were available in the PubMLST Neisseria database for four Burkina Faso 
isolates sequenced as part of this study, and six carriage isolates from Malawi. Analysis of the 
cps locus of the Burkina Faso isolates confirmed the absence of regions A, B and C and the 
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presence of cnl allele 3 flanked by galE allele 365 and tex allele 826 (2). In contrast, the South 
African and Malawi isolates harboured cnl allele 2 flanked by galE allele 161 and tex allele 
235. All galE and tex alleles were unique to cc192 cnl isolates, and were not found in any 
meningococcal isolates in the PubMLST Neisseria database. The Burkina Faso isolates were 
finetype NG: P1.18-11,42: FΔ: ST-192 (cc192) whilst the South African and Malawi isolates 
were NG: P1.18-11,42-2: FΔ: ST-192 (cc192). All 13 isolates harboured allele 112 for the 
fHbp family 3/subfamily A antigen and lacked both the fetA and nadA loci. Eleven of 13 
isolates had allele 621 for NHBA peptide 704. 
 
Ribosomal MLST and cgMLST resolved the 13 cc192 isolates into three groups, which were 
congruent with country of origin. The South African and Malawi isolates were more closely 
related to each other (variable cgMLST loci: 183/959, 19%), compared to the Burkina Faso 
isolates, which differed from the South African meningococci by 201 (21%) loci and the 
Malawi meningococci by 217 (23%) loci, respectively (p=0.06) (Figure 4). Isolate 29306 
from patient two, differed by 13 (1%) and 15 cgMLST loci (2%) from isolates 41961 and 
41860 which were from recurrent IMD episodes in patient three, respectively. Isolates 41961 
and 41860 differed from each other by two cgMLST metabolic loci (0.2%) (Supplementary 
Table 4). Further nucleotide analysis indicated that both genes differed by one nucleotide. 
Overall, 660/959 (69%) of cgMLST loci shared identical nucleotide sequences amongst the 
13 cc192 isolates. 
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CHAPTER FOUR: DISCUSSION 
Four invasive cnl meningococci were detected from three patients, including recurrent IMD 
in a C6 complement deficient patient. There was no epidemiological link between patients, 
and one isolate was NG: P1.7-2,30: F1-2: ST-53 (cc53) whilst the remaining three were NG: 
P1.18-11,42-2: FΔ: ST-192 (cc192). These genotypes were different to invasive cnl isolates 
reported in other countries (2;5;115-117). One invasive isolate did not contain a cnl allele, but 
lacked most genes from regions A and C of the cps. This was similar to that described 
previously in a non-groupable cc41/44 carriage isolate from the USA (41).  
 
Meningococci of cc53 with cnl have previously been found in 7% of N. meningitidis isolates 
from healthy carriers in Germany (40;88). Meningococcal carriage data from the African 
meningitis belt suggest that cc53 is not common in this region (4;173;174) with searches in 
the PubMLST Neisseria database identifying only three other non-groupable cc53 carriage 
isolates from this region: two from Senegal and one in Ethiopia. In addition to an invasive 
Irish isolate which possessed the same finetype as the South African isolate, 11 other invasive 
non-groupable cc53 isolates were identified in Cuba, Cyprus, France and the UK, of which 
six isolates were NG: P1.7,30: F-ND: ST-53 (cc53). Carriage rates are currently unknown in 
South Africa and we have no knowledge of carried genotypes. Although we do not have 
genotypic data for all of our invasive isolates the earliest documentation of any cc53 strain in 
South Africa is the cnl isolate identified in 2006, and described in this study.  
 
In contrast to cc53, cc192 has been reported among carriers in countries of the African 
meningitis belt including Burkina Faso (4), Ghana (174), The Gambia, Ethiopia, Mali, 
Uganda and Niger (PubMLST Neisseria database). According to the PubMLST Neisseria 
database, 95% (72/76) of cc192 isolates were isolated in Africa, and 4% (3/76) isolated in 
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Europe; as opposed to cc53 isolates which were predominantly isolated in Europe (74%, 
312/419) and rarely observed in Africa (1%, 6/419). Furthermore, two cc192 carriage isolates 
were documented in Norway and Sweden, and one case of bacteremia was documented in 
France (PubMLST Neisseria database). The Swedish and French isolates shared the same 
strain designation as the South African and Malawi isolates, however genomic data were 
unavailable for these isolates. Three cases of invasive disease caused by cnl ST-192 isolates 
occurred in Burkina Faso in 2003 and 2004, two of which were included in our study along 
with two carriage isolates from 2003 (2;4). Core genome MLST analysis of 13 African 
isolates revealed three groups of cc192 isolates clustering according to their respective 
countries, however the dataset in this study was limited and more cc192 genomes would be 
required to validate this geographic clustering and fully describe the molecular epidemiology 
of this clone.  
 
The lack of a polysaccharide capsule in disease-associated isolates implies that factors other 
than encapsulation may contribute to the ability of a strain to cause invasive disease, 
including underlying disease conditions of the host. Disease due to unencapsulated 
meningococci and recurrent IMD, have been described in immunocompromised patients who 
are deficient in terminal pathway complement proteins C5 through C9 (108;118;175-178). In 
our study, one patient with C6 deficiency had recurrent IMD with the same cnl strain. A 
similar case was described in the USA in a five-month-old male who was also diagnosed with 
C6 deficiency (118). He was first diagnosed with meningitis followed by bacteremia six 
months later. Both episodes were likely to have been caused by the same unencapsulated 
meningococcal strain, based on the fact that the isolates were non-groupable by phenotypic 
serogrouping and had identical outer membrane vesicle profiles on SDS-PAGE, however 
additional genotypic data were not available for confirmation. These cases of recurrent IMD 
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may suggest persistent carriage in close contacts which is further supported by Mueller et al. 
(4) who identified non-groupable cc192 meningococci at three consecutive monthly visits in 
six healthy carriers in Burkina Faso. In South Africa, chemoprophylaxis is recommended for 
close contacts of IMD patients to eradicate carriage, however this particular strain may have 
persisted within the family. This does not however exclude the possibility that the second 
isolate may have been re-acquired from an individual in the community. Philadelphia 
chromosome-positive (bcr-abl+) common acute lymphatic leukemia was reported in a 
patient with IMD caused by a ST-845 (cc845) cnl isolate in Germany, in 2004 (116). In 
our study, the ST-53 (cc53) isolate was the only organism to be cultured from pleural fluid of 
a patient with empyema, indicating that this isolate was the most likely cause of invasive 
disease. Further, IMD by the ST-53 (cc53) isolate occurred in a patient who was 
immunocompromised due to diabetes mellitus and, in addition, presented with multiple 
chronic illnesses which may have contributed to his susceptibility to invasive disease with a 
cnl strain.  
 
Molecular epidemiology and previous data from serum bactericidal assays (SBA) suggest 
that some groups of meningococci are more inclined to cause invasive disease than others, 
with encapsulated strains being more resistant to complement killing than their 
unencapsulated counterparts (2;115;116;150;179). Although the polysaccharide capsule has 
been shown to be an important virulence determinant, previous SBA data indicate that the 
ability of the invasive cnl ST-192 (cc192) isolates from Burkina Faso to resist complement 
killing in normal human sera, was comparable to an encapsulated serogroup B strain (2). The 
invasive ST-192 (cc192) isolates from Burkina Faso were also determined to be more 
resistant to complement killing than a carriage ST-53 (cc53) isolate and an invasive ST-845 
(cc845) isolate, which had similar resistance profiles to each other and to an unencapsulated 
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serogroup B mutant. Exogenous lipooligosaccharide sialylation significantly increased 
resistance to complement killing in two invasive cnl isolates belonging to ST-198 (cc198), 
and was partially attributed to their ability to cause invasive disease in apparently healthy 
patients (5;115). However, this mechanism was not identified in the invasive ST-192 (cc192) 
isolates from Burkina Faso, the carriage ST-53 (cc53) isolate and the invasive ST-845 
(cc845) isolate (2).  
 
In agreement with previous genome studies, most putative virulence loci were present in both 
carriage and invasive cnl isolates (75;154;155). Although Joseph et al. (71) determined 
significant associations of mobile genetic elements with invasive meningococci, their 
contribution to meningococcal virulence is unknown. The ability of cnl isolates to cause 
invasive disease may likely be due to host risk factors, however differences in the virulence 
potential may also be explained by variation in gene expression. Predisposing factors for one 
patient with invasive disease that was caused by an ST-192 (cc192) isolate, were unknown. It 
is likely that this patient may have also presented with underlying disease, however SBA data 
for the invasive ST-192 (cc192) isolates from Burkina Faso, indicate that these isolates may 
cause invasive disease in healthy patients. In contrast, cc53 which was previously shown to 
be sensitive to normal human sera, may require an immunocompromised host to cause IMD, 
as demonstrated in our study. We did not perform SBA’s to confirm these findings. 
 
In South Africa, the quadrivalent polysaccharide vaccine and the quadrivalent conjugate 
vaccine which was recently introduced in 2015, are recommended for individuals with 
terminal complement deficiencies and may be offered to close contacts of IMD patients 
following post-exposure chemoprophylaxis. The vaccination status of all three patients as 
well as the contacts for the first two were unknown, however the mother of the patient with 
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C6 deficiency was administered a single dose of Menactra®, which is ineffective in 
preventing carriage of cnl meningococci which lack a capsule. All 94 cnl meningococci 
including those analyzed in this study lacked the nadA locus and the P1.4 antigen; and most 
isolates expressed fHbp variants which are not targeted by the Bexsero® vaccine (with the 
exception of isolates that belong to cc198 and cc41/44, which express variant 1 fHbp). The 
effectiveness of Bexsero® to target cnl meningococci in general would therefore be largely 
reliant on the expression and cross protective potential of NHBA (180). Although the bivalent 
fHbp vaccine Trumenba® potentially elicits broad spectrum bactericidal activity against 
serogroup B strains, its effect on fHbp variants and their level of expression in other 
serogroups and cnl meningococci is unknown (181). 
 
Invasive meningococcal disease by cnl meningococci in South Africa is rare however such 
strains may have a heightened tendency to cause IMD in an immunocompromised host, 
potentially coupled with currently unknown non-capsular virulence mechanisms in the 
meningococcus.  
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CHAPTER FIVE: CONCLUSION  
Through our robust and stable laboratory-based surveillance for IMD, we detected three cases 
of IMD caused by unencapsulated (cnl) N. meningitidis, including a repeat infection in one 
individual. One isolate belonged to lineage cc53 and, at the time of analysis, this clonal 
complex was most frequently identified in healthy carriers in Europe and the UK (PubMLST 
Neisseria database), however recent data from Southern Ethiopia reported ~10% of isolates 
from healthy carriers to be cc53 (99). The three remaining isolates were cc192 which was 
reported to be common amongst healthy carriers in the African meningitis belt (4;99;174).  
 
The use of TEM in conjunction with phenotypic and genotypic data was used to confirm the 
absence of a capsule. Several previously described TEM assays were evaluated to visualize 
polysaccharide capsules from Gram-positive and Gram-negative bacteria (1). The use of 
formaldehyde-glutaraldehyde ruthenium red-osmium fixation was recommended for 
visualizing capsules expressed by Gram-positive bacteria, but was unable to stain capsules 
from N. meningitidis serogroup A. The use of alcian blue (pyridine variant) as a substitute for 
ruthenium red was recommended for Gram-negative bacteria, but occasionally demonstrated 
non-specific staining between unencapsulated meningococci. Considering that the TEM 
methods evaluated for the current study do not conclusively represent the presence of a 
capsule, the inclusion of positive and negative controls in addition to replicates are 
emphasized. Future validations should therefore aim to improve on or develop TEM assays 
which provide reliable results by for example, evaluating the performance additional cationic 
dyes on a broad collection of Gram-negative and Gram-positive isolates with variable capsule 
compositions. 
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The use of whole genome sequencing provided high resolution molecular characterization of 
these unusual N. meningitidis isolates and insight into the individual cases. Further, the 
PubMLST Neisseria database provided a standardized, portable, user-friendly platform for 
comparison of data with other publically available genomes from geographically distinct 
clinical isolates of the same lineage (77). Genomic data confirmed the phenotypic lack of 
capsule, and the presence/ absence of vaccine antigens and currently known virulence 
determinants. Although genome data may provide information on the presence of loci as well 
as their translated protein products, it does not indicate gene expression. This information is 
particularly important for determining vaccine effectiveness and virulence mechanisms, and 
should therefore be evaluated in future studies.  
 
Consistent with previous genome studies, most putative virulence loci were identified in both 
carriage and invasive cnl meningococci analyzed in this study (71;75). In contrast, Schork et 
al. (182) identified a full length opc locus and a second pilC locus in a cc198 cnl isolate 
which displayed higher adhesion and invasion rates, compared to a cc53 carriage isolate. This 
comparison was however limited to two cnl genomes. Differences in pathogenic potential 
may be explained by variable expression of virulence loci in addition to those involved in 
processes such as metabolism and information processing (183;184). Considering that 
N. meningitidis is a strict human pathogen, the development of animal models to investigate 
virulence mechanisms of this pathogen in vivo is difficult. Alternatively, ex vivo models 
which mimic the human host together with systems biological approaches (including the use 
of microarrays) may be used to evaluate the expression of meningococcal virulence factors 
and determine potential differences between carried and invasive cnl meningococci (183). 
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The variable expression of virulence factors in cnl meningococci may also be highlighted by 
previous studies that demonstrate varying susceptibilities of cnl isolates to human sera, which 
may be linked to their ability to modify their cell surface by sialylation of the LPS, using 
exogenous sources of sialic acid (115). This mechanism was identified in invasive cc198 cnl 
isolates and increased their resistance to human sera, but was not used by cnl isolates 
belonging to cc845, cc53 and cc192 (2). In contrast to cc845 (invasive) and cc53 (carriage), 
the invasive Burkina Faso isolates belonging to cc192 were determined to be resistant to 
killing by human sera and may therefore cause disease in both immunocompentent and 
immunocompromised individuals. Considering that SBA’s were not performed for the 
invasive South African cnl isolates, the virulence potential of these strains should also be 
further investigated. In addition, carriage data in South Africa will be useful to elucidate the 
circulation of these ‘potentially’ virulent strains. It is also recommended that the sodC target 
should be used to screen for IMD, which detects both unencapsulated and encapsulated 
meningococci, as opposed to ctrA which detects encapsulated isolates only. In our laboratory, 
both assays are used routinely. 
 
Susceptibility to IMD by cnl meningococci may be influenced by host risk factors. One 
patient with C6 deficiency experienced two episodes of IMD, eight months apart. Whole 
genome analysis confirmed that the second IMD episode was caused by the identical strain. 
This observation suggests persistent carriage within the household or community and 
highlights the importance of administering chemoprophylaxis to close contacts upon 
identification of an IMD case, regardless of meningococcal encapsulation. Previous data 
suggest that protein-based vaccines such as Bexsero® and Trumenba® may have the potential 
to target non-serogroup B meningococci (185), including those harbouring a cnl (180). The 
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cnl meningococci analysed in this study (n=93) expressed fHbp (cc198 and cc41/44 
specifically contained loci for variant 1 fHbp) and NHBA which was reported to be cross-
reactive (142). Most cnl meningococci expressed fHbp variants 2 and 3 which were reported 
to be cross-reactive with each other, but not with variant 1 which is present in Bexsero® (64). 
Although the nadA locus was absent in all cnl isolates, NadA-1, NadA-2 and NadA-3 
antigens were also shown to be cross-reactive (59). It was further established that 
immunogenicity to at least one target in Bexero® was sufficient to confer protection against 
IMD (186). The bivalent fHbp vaccine Trumenba® also conferred broad protection against 
variants expressed by serogroup B (146;181). Immunocompromised patients may therefore 
benefit from these vaccines for long-term protection. Serogroup B vaccines are however not 
available in South Africa. The mother of the patient with C6 deficiency received a single dose 
of the quadrivalent conjugate meningococcal vaccine which provides immunity and reduces 
carriage of serogroups A, C, W and Y; but does not confer protection against other 
serogroups and unencapsulated strains. The vaccination status of the C6 deficient patient was 
unknown, however he was put onto life-long treatment with penicillin. To provide long-term 
immunity, vaccination with the quadrivalent conjugate meningococcal vaccine is also 
recommended for individuals with complement deficiency in South Africa, although life-long 
treatment with penicillin may be considered to prevent recurrent IMD episodes.  
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APPENDICES 
Supplementary material 
 
 
 
Figure S1. Workflow of phenotypic and genotypic methods used to characterize invasive capsule null 
Neisseria meningitidis isolates detected through the national laboratory-based surveillance in South Africa, 
from 2003 through 2013. 
82 
 
 
Table S1. Primers and probes used in real-time PCR assays for the detection of encapsulated and unencapsulated Neisseria meningitidis (32). 
Organism Target Sequence 5'→3' 
Concentration 
(nM) 
N. meningitidis (encapsulated and 
unencapsulated)  sodC a Forward GCACACTTAGGTGATTTACCTGCAT 300 
  
Reverse CCACCCGTGTGGATCATAATAGA 600 
  
Probe FAM-CATGATGGCACAGCAACAAATCCTGTTT-BHQ1 100 
N. meningitidis (encapsulated)  ctrA b Forward TGTGTTCCGCTATACGCCATT 300 
  
Reverse GCCATATTCACACGATATACC 900 
  
Probe FAM-AACCTTGAGCAA/BHQ1-dT/CCATTTATCCTGACGTTCT 100 
N. meningitidis serogroup A csaB b Forward AAAATTCAATGGGTATATCACGAAGA  300 
  
Reverse ATATGGTGCAAGCTGGTTTCAATAG 900 
  
Probe HEX-CTAAAAG/BHQ1-dT/AGGAAGGGCACTTTGTGGCATAAT  100 
N. meningitidis serogroup B csb b Forward GCTACCCCATTTCAGATGATTTGT 300 
  
Reverse ACCAGCCGAGGGTTTATTTCTAC 300 
  
Probe QUAS670 -AAGAGATGGGYAACAAC/BHQ2-dT/ATGTAATGTCTTTATTT  100 
N. meningitidis serogroup C csc b Forward CCCTGAGTATGCGAAAAAAATT 900 
  
Reverse TGCTAATCCCGCCTGAATG 300 
  
Probe FAM-TTTCAATGC/BHQ1-dT/AATGAATACCACCGTTTTTTTGC  100 
N. meningitidis serogroup W csw b Forward TATTTATGGAAGGCATGGTGTATG 100 
  
Reverse TTGCCATTCCAGAAATATCACC  900 
  
Probe FAM-AAATATGGAGCGAA/BHQ1-dT/GATTACAGTAACTATAA  200 
N. meningitidis serogroup X csxB b Forward TGTCCCCAACCGTTTATTGG 900 
  
Reverse TGCTGCTATCATAGCCGCC 900 
  
Probe QUAS670 TGTTTGCCCACATGAATGGCGG-BHQ2 100 
N. meningitidis serogroup Y csy b Forward TCCGAGCAGGAAATTTATGAGAATAC 900 
  
Reverse TTGCTAAAATCATTCGCTCCATAT 600 
    Probe HEX-TATGGTG/BHQ1-dT/ACGATATCCCTATCCTTGCCTATAAT 100 
BHQ, black hole quencher 
a: The assay uses 12.5 µl of Taqman mastermix (Applied Biosystems, California, USA), per sample.  
b: The assay uses 12.5 µl of Invitrogen mastermix (Applied Biosystems, California, USA) and 0.5 µl of 1:10 ROX, per sample. 
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Figure S2. Nucleotide sequences of capsule null locus (cnl) alleles identified in invasive and carried Neisseria meningitidis isolates analyzed in this study 
(n=93), PubMLST Neisseria database locus identifier: NEIS2743. 
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Table S2. Epidemiological information, molecular characterization and genome characteristics of all Neisseria meningitidis isolates analyzed in 
this study (n=94) a.  
Clonal 
complex 
PubMLST 
id 
ENA 
accession 
Country 
of 
Origin 
Year of 
isolation 
Infection 
status 
Strain designation 
Approx 
genome size 
(bp) 
No. of 
contigs 
N50 (bp) 
fHbp 
family/ 
fHbp 
subfamily 
NHBA 
peptide 
ST-53 30 
None 
Germany 1999 Carriage 
NG: P1.7,30-3: F5-5: ST-53 
(cc53) 
2145295 1 2145295 2/A 58 
 
972 
ERR133719 
Czech 
Republic 
1993 Carriage 
NG: P1.7,30: F1-2: ST-53 
(cc53) 
2086958 177 34059 2/A 58 
 
984 
ERR133728  
Czech 
Republic 
1993 Carriage 
NG: P1.7,30-2: F1-13: ST-53 
(cc53) 
2086353 155 40656 2/A 58 
 
1639 
ERR137118 
Czech 
Republic 
1993 Carriage 
NG: P1.7,30: F1-2: ST-53 
(cc53) 
2095123 198 34225 2/A 58 
 
1649 
ERR137128 
Czech 
Republic 
1993 Carriage 
NG: P1.7,30: F1-13: ST-53 
(cc53) 
2088196 150 41128 2/A 58 
 
1654 
ERR137131 
Czech 
Republic 
1993 Carriage 
NG: P1.7,30-2: F1-13: ST-
123 (cc53) 
2086742 169 34341 2/A 58 
 
2222 
ERR137150 
Czech 
Republic 
1993 Carriage 
NG: P1.7,30-4: F3-9: ST-124 
(cc53) 
2100494 175 39068 2/A 58 
 
8169 
ERR137184 
Czech 
Republic 
1993 Carriage 
NG: P1.7,30-5: F1-13: ST-53 
(cc53) 
2098030 152 37525 2/A 58 
 
8177 
ERR133778 
Czech 
Republic 
1993 Carriage 
NG: P1.12-4,16-8: F1-13: ST-
53 (cc53) 
2100968 163 33949 2/A 58 
 
8181 
ERR133782 
Czech 
Republic 
1993 Carriage 
NG: P1.7,30: F1-2: ST-53 
(cc53) 
2091984 194 33426 2/A 58 
 
26253 
ERR406569 
UK 2011 Carriage 
NG: P1.7,30-7: F1-2: ST-53 
(cc53) 
2098335 184 42342 2/A 58 
 
26263 
ERR406579 
UK 2011 Carriage 
NG: P1.7-2,30-5: F1-2: ST-53 
(cc53) 
2094245 171 45788 2/A 58 
 
26267 
ERR406583 
UK 2011 Carriage 
NG: P1.7,30-2: F1-2: ST-53 
(cc53) 
2089516 127 62828 2/A 58 
 
26271 ERR406587 UK 2012 Carriage NG: P1.7,30-3: F1-2: ST-53 2085831 181 53110 2/A 58 
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(cc53) 
 
26274 
ERR406590 
UK 2012 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2099254 163 46913 2/A 58 
 
26283 
ERR406599 
UK 2011 Carriage 
NG: P1.7,30: F1-2: ST-2441 
(cc53) 
2093733 141 72612 2/A 58 
 
26320 
ERR406636 
UK 2011 Carriage 
NG: P1.7,30-5: F1-210: ST-
53 (cc53) 
2084589 152 49846 2/A 58 
 
26325 
ERR406641 
UK 2012 Carriage 
NG: P1.7,30-2: F1-2: ST-53 
(cc53) 
2099528 153 48389 2/A 58 
 
26326 
ERR406642 
UK 2011 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2095080 173 40353 2/A 58 
 
26336 
ERR406652 
UK 2012 Carriage 
NG: P1.7,30-2: F1-2: ST-53 
(cc53) 
2095257 146 57623 2/A 58 
 
26344 
ERR406660 
UK 2011 Carriage 
NG: P1.7-2,30-1: F1-2: ST-53 
(cc53) 
2091793 154 57928 2/A 58 
 
26350 
ERR406665 
UK 2011 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2074823 203 37591 2/A 58 
 
26355 
ERR406670 
UK 2011 Carriage 
NG: P1.7,30-5: F1-2: ST-53 
(cc53) 
2102044 188 42480 2/A 58 
 
26365 
ERR406680 
UK 2012 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2093125 179 45837 2/A 58 
 
26372 
ERR406687 
UK 2012 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2104019 159 42723 2/A 58 
 
26382 
ERR406697 
UK 2011 Carriage 
NG: P1.7,30-5: F1-210: ST-
53 (cc53) 
2084160 181 45756 2/A 58 
 
26383 
ERR406698 
UK 2011 Carriage 
NG: P1.7,30-2: F1-2: ST-53 
(cc53) 
2098926 192 43087 2/A 58 
 
26394 
ERR406709 
UK 2011 Carriage 
NG: P1.7,30: F1-2: ST-2441 
(cc53) 
2087485 217 38541 2/A 58 
 
26399 
ERR406714 
UK 2011 Carriage 
NG: P1.7,30: F1-2: ST-53 
(cc53) 
2115750 202 40895 2/A 58 
 
26402 
ERR406717 
UK 2011 Carriage 
NG: P1.7,30-2: F1-2: ST-53 
(cc53) 
2093395 199 40014 2/A 58 
 
26415 
ERR406730 
UK 2011 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2091254 212 40601 2/A 58 
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26419 
ERR406734 
UK 2011 Carriage 
NG: P1.7,30: F1-2: ST-53 
(cc53) 
2102519 171 45735 2/A 58 
 
26444 
ERR406759 
UK 2011 Carriage 
NG: P1.7,30-7: F1-2: ST-53 
(cc53) 
2099273 212 37220 2/A 58 
 
26445 
ERR406760 
UK 2012 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2100574 163 37850 2/A 58 
 
26451 
ERR406766 
UK 2011 Carriage 
NG: P1.7,30: F1-2: ST-53 
(cc53) 
2081029 171 45568 2/A 58 
 
26457 
ERR406772 
UK 2011 Carriage 
NG: P1.7,30: F1-2: ST-53 
(cc53) 
2099175 184 39403 2/A 58 
 
26466 
ERR406781 
UK 2012 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2095506 214 35648 2/A 58 
 
26474 
ERR406789 
UK 2011 Carriage 
NG: P1.7,30-2: F1-2: ST-53 
(cc53) 
2100594 148 45514 2/A 58 
 
26500 
ERR406815 
UK 2012 Carriage 
NG: P1.7,30-2: F1-2: ST-53 
(cc53) 
2097852 179 41400 2/A 58 
 
26518 
ERR406833 
UK 2012 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2098884 155 42430 2/A 58 
 
26522 
ERR406837 
UK 2012 Carriage 
NG: P1.7,30: F1-2: ST-2441 
(cc53) 
2099850 135 80891 2/A 58 
 
29312 
ERR519789 
South 
Africa 
2006 Invasive 
NG: P1.7-2,30: F1-2: ST-53 
(cc53) 
2104685 119 43300 2/A 191 
 
36135 
ERR976864 
Ireland 2012 Invasive 
NG: P1.7,30: F1-6: ST-53 
(cc53) 
2105077 119 63772 2/A 58 
 
38889 
None 
Italy 2012 Carriage 
NG: P1.7,30: F1-5: ST-53 
(cc53) 
2049750 189 18121 2/A 58 
 
38943 
None 
Italy 2013 Carriage 
NG: P1.7,30-3: F1-2: ST-53 
(cc53) 
2071425 159 22868 2/A 58 
 
38946 
None 
Italy 2013 Carriage 
NG: P1.18-1,3: F1-2: ST-53 
(cc53) 
2027967 250 13654 2/A 58 
 
38953 
None 
Italy 2013 Carriage 
NG: P1.7,30: F1-2: ST-53 
(cc53) 
2055930 176 19654 2/A 58 
 
38954 
None 
Italy 2013 Carriage 
NG: P1.7,30: F1-7: ST-11167 
(cc53) 
2066728 175 20704 2/A 58 
 
38956 None Italy 2013 Carriage NG: P1.7,30-2: F1-5: ST- 2053748 195 18393 2/A 58 
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11133 (cc53) 
 
 
 
         
ST-198 21389 
ERR310995 
Austria 2012 Invasive 
NG: P1.18,25-15: F5-5: ST-
823 (cc198) 
2072066 138 51459 1/B 10 
 
26328 
ERR406644 
UK 2012 Unknown 
NG: P1.18,25: F5-5: ST-823 
(cc198) 
2089889 113 74092 1/B 10 
 
26362 
ERR406677 
UK 2011 Unknown 
NG: P1.18,25: F5-5: ST-823 
(cc198) 
2090590 157 53622 1/B 10 
 
26376 
ERR406691 
UK 2011 Unknown 
NG: P1.18,25-1: F5-5: ST-
10479 (cc198) 
2098591 200 39537 3/A 10 
 
26454 
ERR406769 
UK 2011 Unknown 
NG: P1.5-2,10-49: F5-5: ST-
823 (cc198) 
2084975 193 37200 1/B 10 
 
26458 
ERR406773 
UK 2012 Unknown 
NG: P1.5-2,10-49: F5-5: ST-
823 (cc198) 
2080243 196 36697 1/B 10 
 
26481 
ERR406796 
UK 2011 Unknown 
NG: P1.18,25-1: F5-5: ST-
10479 (cc198) 
2099838 168 51372 3/A 10 
 
26483 
ERR406798 
UK 2012 Unknown 
NG: P1.5-2,10-49: F5-5: ST-
823 (cc198) 
2083366 131 48987 1/B 10 
 
26495 
ERR406810 
UK 2012 Unknown 
NG: P1.18,25-37: F5-5: ST-
823 (cc198) 
2080149 166 54249 1/B 10 
 
26523 
ERR406838 
UK 2011 Unknown 
NG: P1.18,25: F5-5: ST-823 
(cc198) 
2086643 113 55637 1/B 10 
 
28109 
ERR473176 
UK 2013 Invasive 
NG: P1.18,25-14: F-ND: ST-
823 (cc198) 
2077201 143 37036 1/B 10 
 
37603 
None 
Canada Unknown Invasive 
NG: P1.19,ND: F5-5: ST-198 
(cc198) 
2154992 25 7593 3/A 10 
 
34635 
None 
USA 1998 Carriage 
NG: P1.18,25-1: F5-5: ST-
198 (cc198) 
1912936 360 188031 3/A 10 
 
 
 
         
ST-1136 19999 
ERR170970 
UK 2010 Invasive 
NG: P1.12-17,4-1: F3-6: ST-
1136 (cc1136) 
2061868 144 42306 3/A 554 
 
20568 
None 
Canada 2009 Invasive 
NG: P1.18-4,25: F4-1: ST-
1136 (cc1136) 
2056076 152 27668 3/A 145 
 
26351 
ERR406666 
UK 2012 Unknown 
NG: P1.18-4,25: F4-1: ST-
10480 (cc1136) 
2109512 196 34884 3/A 145 
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26422 
ERR406737 
UK 2011 Unknown 
NG: P1.18-4,25: F4-1: ST-
10480 (cc1136) 
2088468 233 33274 3/A 145 
 
36133 
ERR976874 
Ireland 2015 Invasive 
NG: P1.18-4,25-31: F3-9: ST-
1136 (cc1136) 
2148812 108 55646 3/A 145 
 
36815 
ERR957608  
Ireland 2015 Invasive 
NG: P1.18-4,25-31: F3-9: ST-
1136 (cc1136) 
2149725 116 56198 3/A 145 
 
 
 
         
ST-41/44 26288 
ERR406604 
UK 2012 Unknown 
NG: P1.17,16-3: F5-5: ST-
3243 (cc41/44) 
2163495 180 52379 1/B 710 
 
26293 
ERR406609 
UK 2012 Unknown 
NG: P1.7-2,2: F1-5: ST-41 
(cc41/44) 
2098529 154 40808 1/B 2 
 
26378 
ERR406693 
UK 2012 Unknown 
NG: P1.7-2,4: F1-5: ST-41 
(cc41/44) 
2102654 198 36139 1/B 2 
 
26463 
ERR406778 
UK 2011 Unknown 
NG: P1.7-2,4: F1-5: ST-41 
(cc41/44) 
2097257 176 45840 1/B 2 
 
26484 
ERR406799 
UK 2011 Unknown 
NG: P1.17,16-3: F5-5: ST-
3243 (cc41/44) 
2166337 228 36888 1/B 710 
 
26485 
ERR406800 
UK 2011 Unknown 
NG: P1.7-2,4: F1-5: ST-41 
(cc41/44) 
2105468 190 43673 1/B 2 
 
26492 
ERR406807 
UK 2011 Unknown 
NG: P1.7-2,4: F1-5: ST-41 
(cc41/44) 
2101154 137 45970 1/B 2 
 
38927 
None 
Italy 2013 Carriage 
NG: P1.18-1,3: F1-84: ST-
414 (cc41/44) 
2090003 167 22192 2/A 2 
 
  37616 c  ERR519785 
South 
Africa 
2013 Invasive 
NG: P1.7-1,1: F3-20: ST-
11147 (cc41/44) 
2016190 181 19967 2/A 312 
 
 
 
         
ST-1117 26341 
ERR406657 
UK 2012 Unknown 
NG: P1.7-1,1: F3-7: ST-1117 
(cc1117) 
2114682 156 39419 2/A 239 
 
26998 
ERR351662 
UK Unknown Unknown 
NG: P1.18-1,30: F3-7: ST-
1117 (cc1117) 
2108735 214 32834 2/A NDb 
 
26999 
ERR351663 
UK Unknown Unknown 
NG: P1.18-1,30: F3-7: ST-
1117 (cc1117) 
2108209 214 32838 2/A 239 
 
 
 
         
ST-213 26467 
ERR406782 
UK 2012 Unknown 
NG: P1.22,14: F5-5: ST-213 
(cc213) 
2224812 255 37780 2/A 248 
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ST-192 29306 
ERR519863 
South 
Africa 
2010 Invasive 
NG: P1.18-11,42-2: FΔ: ST-
192 (cc192) 
2040849 111 46259 3/A 704 
 
41961 
ERR1805705 
South 
Africa 
2011 Invasive 
NG: P1.18-11,42-2: FΔ: ST-
192 (cc192) 
1995940 447 7344 3/A NDb 
 
41860 
ERR1805704 
South 
Africa 
2012 Invasive 
NG: P1.18-11,42-2: FΔ: ST-
192 (cc192) 
2003633 489 7130 3/A NDb 
 
35416 
ERR903637 
Burkina 
Faso 
2003 Invasive 
NG: P1.18-11,42: FΔ: ST-192 
(cc192) 
2022469 252 19910 3/A 704 
 
35417 
ERR903631 
Burkina 
Faso 
2003 Invasive 
NG: P1.18-11,42: FΔ: ST-192 
(cc192) 
2025752 264 21188 3/A 704 
 
35418 
ERR903647 
Burkina 
Faso 
2004 Carriage 
NG: P1.18-11,42: FΔ: ST-192 
(cc192) 
2024513 227 24711 3/A 704 
 
35419 
ERR903634 
Burkina 
Faso 
2004 Carriage 
NG: P1.18-11,42: FΔ: ST-192 
(cc192) 
2020581 292 19063 3/A 704 
 
42224 
None 
Malawi 2005 Carriage 
NG: P1.18-11, 42-2: FΔ: ST-
192 (cc192) 
2040471 94 56858 3/A 704 
 
42227 
None 
Malawi 2005 Carriage 
NG: P1.18-11, 42-2: FΔ: ST-
192 (cc192) 
2042345 104 56856 3/A 704 
 
42237 
None 
Malawi 2005 Carriage 
NG: P1.18-11, 42-2: FΔ: ST-
192 (cc192) 
2042666 107 56858 3/A 704 
 
42238 
None 
Malawi 2005 Carriage 
NG: P1.18-11, 42-2: FΔ: ST-
192 (cc192) 
2041750 96 53482 3/A 704 
 
42251 
None 
Malawi 2006 Carriage 
NG: P1.18-11, 42-2: FΔ: ST-
192 (cc192) 
2042182 100 54124 3/A 704 
  42256 None Malawi 2006 Carriage 
NG: P1.18-11,42-2: FΔ: ST-
192 (cc192) 
2041768 98 54124 3/A 704 
 
a: nadA was absent in all isolates analyzed; b: sequence data for nhba are incomplete; c: PubMLST ID 37616 is an invasive unencapsulated N. meningitidis 
isolate which lacks the genes required for polysaccharide synthesis and transport in regions A and C of the capsule polysaccharide synthesis locus, but does 
not possess the capsule null locus, and was therefore excluded from further analysis 
Abbreviations: fHbp, factor-H binding protein; NHBA, neisserial heparin-binding antigen; NG, nongroupable; P1, PorA; F, FetA; ST, sequence type; cc, 
clonal complex; Δ, gene deletion; ND: not defined. 
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Table S3. Putative virulence loci (n=117) analyzed in 51 carriage and 14 invasive capsule 
null meningococci (75).  
Gene 
PubMLSTNeisseria 
database locus 
identifier 
Function 
env/lpxC NEIS0001 
UDP-3-O-[3-hydroxymyristoyl] N-
acetylglucosaminedeacetylase 
kdtA NEIS2152  3-deoxy-D-manno-octulosonic-acid transferase 
lgtA NEIS1902 Lacto-N-neotetraose biosynthesis glycosyltransferase 
lgtB NEIS1901 Lacto-N-neotetraose biosynthesis glycosyltransferase 
lgtE NEIS1900 Lacto-N-neotetraose biosynthesis glycosyltransferase 
lgtF NEIS1618 Beta-1,4 glucosyltransferase 
lst NEIS0899 Alpha-2,3-sialyltransferase 
rfaC NEIS2134 Heptosyltransferase I 
lpxA NEIS0168 UDP-N-acetylglucosamineacyltransferase 
lpxB NEIS0191 Lipid-A-disaccharide synthase  
lpxD NEIS0171 UDP-3-O-[3-hydroxymyristoyl] glucosamine N-acyltransferase  
pgm NEIS0743 Phosphoglucomutase 
rfaD NEIS0773 ADP-D-beta-D heptoseepimerase 
rfaE NEIS0769  D-beta-D-heptose-7-phosphate kinase 
rfaF NEIS1456 Heptosyltransferase II 
rfaK NEIS1619 Alpha-1,2 N-acetylglucosaminetransferase 
nadA NEIS1969 Adhesin/invasin 
omp85 NEIS0173 Outer membrane protein OMP85 
ompH NEIS0172 Putative outer membrane protein 
opa NEIS1719 Opa1800 OMP 
opcA NEIS2198 OpcA 
opcB NEIS1877 Hypothetical protein 
pglA NEIS0213 Pilin glycosyltransferase 
pglB NEIS0399 Protein glycosylation 
pglC NEIS0397 Pilin glycosylation protein 
pglD NEIS0396 Pilin glycosylation protein 
pilC1 NEIS0371 Type IV pilus associated protein 
pilC2 NEIS0033 Type IV pilus associated protein 
pilE NEIS0210 Pilus genes 
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pilF  NEIS1844 Pilus genes 
pilG  NEIS1838 Pilus genes 
pilT-1  NEIS0036 Type IV pilus retraction ATPase PilT 
pilT-2  NEIS0721 pilT_like protein 
pilV NEIS0487 Minor pilin 
porA NEIS1364 PorA, porin, class 1 outer membrane protein 
rmpM NEIS1783 Outer membrane protein class 4 
- NEIS2438 
Putative large exoprotein involved in heme utilization or 
adhesion of ShlA/HecA/FhaA family 
- NEIS0444 hemagglutinin 
- NEIS0443 TpsA activation/secretion protein TpsB 
bcp NEIS0704 Hypothetical protein 
bfrA NEIS1108 Bacterioferritin A 
bfrB NEIS1107 Bacterioferritin B 
fbpA NEIS0578 Major ferric iron binding protein 
fbpB NEIS0577 Putative iron-uptake permease inner membrane protein 
fetB2 NEIS0340 Ferric enterobactin transporter binding protein 
fur NEIS0197 Ferric uptake regulation protein 
- NEIS1966 Putative inner membrane transport protein 
- NEIS1965 Putative inner membrane transport protein 
- NEIS1964 Putative membrane transport solute-binding protein 
lbpA NEIS1468 Lactoferrin binding protein A 
lbpB NEIS1469 Lactoferrin binding protein B 
tbpA NEIS1690 Transferrin binding protein A 
tbpB NEIS1691 Transferrin binding protein B 
- NEIS1887 TonB-dependent receptor protein, FhuA 
- NEIS0338 Ferric siderophore receptor protein 
- NEIS0387 TonB-dependent receptor 
- NEIS1282 Putative TonB-dependent receptor protein 
nhba NEIS2109 Putative periplasmic protein 
tspA NEIS1829 Neisseria-specific antigen protein TspA 
tspB NEIS1866 TspB protein 
- NEIS1806 putative zinc-binding protein 
- NEIS1805 hypothetical protein 
frpC NEIS1344 RTX iron-regulated frpc protein outer membrane 
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- NEIS1560 Hemolysin 
- NEIS2434 RTX toxin activating lysine-acyltransferase  
- NEIS2502 putative FrpA/C-activating lysine-acyltransferase 
dsbA NEIS1760 Putative thiol:disulphide interchange protein 
dsbA NEIS1885 Thiol:disulfide interchange protein 
dsbA NEIS0273 Putative thiol:disulphide interchange protein 
iga NEIS0651 IgA1 protease 
kat NEIS0211 Catalase (KatA) 
sodB NEIS0825 Superoxide dismutase sodB 
sodC NEIS1339 Superoxide dismutase sodC 
- NEIS0035 PilT-like protein 
- NEIS2495 putative VapD-like protein 
- NEIS2103 putative protease 
- NEIS0528 putative periplasmic binding protein 
- NEIS0978 putative surface fibril protein 
- NEIS1658 periplasmic type I secretion system protein 
- NEIS1750 hypothetical protein 
fabZ NEIS0170 3R-hydroxymyristoyl ACP dehydrase 
gna1870 NEIS0349 Factor H-binding protein 
gna1946 NEIS1917 Putative lipoprotein 
hap NEIS1959 IgA-specific serine endopeptidase 
hemH NEIS0669 Ferrochelatase 
hemH NEIS0709 Phosphoribosylaminoimidazole-succinocarboxamide synthase 
misR/phoP NEIS0537 Putative two-component system regulator 
misS/phoQ NEIS0536 Putative two-component system sensor kinase 
mtrC NEIS1634 Membrane fusion protein 
mtrD NEIS1633 Drug efflux protein 
mtrE NEIS1632 Putative outer membrane lipoprotein 
mtrR NEIS1635 Transcriptional regulator mtR 
narE NEIS2492 ADP-ribosyltransferaseNarE 
natC NEIS1657 natC, periplasmic type I secretion system protein 
nlpD NEIS1418 Putative membrane peptidase 
norZ NEIS1548 Nitric oxide reductase 
nspA NEIS0612 Outer membrane protein 
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nth NEIS0472 Endonuclease III 
prc NEIS1270 Putative carboxy-terminal processing protease 
vacJ NEIS1933 Periplasmic/outer membrane protein 
vapA NEIS1859 Autotransporter A VapA 
virG NEIS1454 Virulence associated protein 
ctrG NEIS0049 Putative transcriptional accessory protein 
csc NEIS0051  polysialyltransferase 
ctrA NEIS0055  capsule polysaccharide export outer membrane protein 
ctrB NEIS0056  capsule polysaccharide export inner membrane protein 
ctrC NEIS0057  capsule polysaccharide export inner membrane protein 
ctrD NEIS0058  capsule polysaccharide export ATP-binding protein 
ctrE NEIS0066  capsule translocation 
ctrF NEIS0067  capsule translocation 
csaA NEIS2157  csaA / UDP-N-acetyl-D-glucosamine 2-epimerase 
csaB NEIS2158  csaB / polymerase linking UDP-ManNAc monomers 
csaC NEIS2159  csaC / O-acetyltransferase 
csaD NEIS2160  csaD / capsule transport 
csb NEIS2161  polysialyltransferase 
csw NEIS2162  D-galactose and sialic acid 
csy NEIS2163  D-glucose and sialic acid 
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Table S4. Variable core loci (n=2) identified in clonal complex 192 capsule null Neisseria meningitidis isolates 41860 and 41961, obtained from 
a patient who experienced two episodes of invasive meningococcal disease in 2011 and 2012, respectively. 
 
Abbreviations: SNP, Single nucleotide polymorphism
PubMLST 
locus ID 
Alternate  
locus ID 
PubMLST allele 
Gene length 
(bp) 
SNP 
position 
SNP Product Function 
    
Isolate 
41961 
Isolate 
41860           
NEIS0406 NMB1814 71 292 1080 954 G→A 
3-dehydroquinate 
synthase 
Amino acid metabolism 
NEIS1155 NMB1254 12 241 594 513 C→T 
GTP cyclohydrolase 
II 
 Metabolism of cofactors 
and vitamins 
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